Publications

Crooke, S.T., Baker, B.F., Crooke R.M., Liang, X.H. Antisense Technology: An Overview and Prospectus. Nature Drug Discovery, 2021. in press

Prakash TP., Yu J., Shen W., Hoyos CL., Berdeja A., Gaus H., Liang XH., Crooke, S.T., Seth, P. Site-specific Incorporation of 2’,5’-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. ACS Medicinal Chemistry Letter, 2021. submitted

Guillermo Vasquez, Graeme C Freestone, W Brad Wan, Audrey Low, Cheryl Li De Hoyos, Jinghua Yu, Thazha P Prakash, Michael E Ǿstergaard, Xue-hai Liang, Crooke, S.T., Eric E Swayze, Michael T Migawa, Punit P Seth, Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs, Nucleic Acids Research, 2021. [published online ahead of print]

Crooke, S.T., Baker, B.F., Crooke R.M., Liang, X.H. Antisense technology a broadly enabling drug discovery technology? Moclecular mechanisms. J Biological Chemisrty 2021. [published online ahead of print]

Zhang, L., Vickers, T.A, Sun, H., Liang, X.H., Crooke, S.T. Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins. Nucleic Acids Res. 2021. [published online ahead of print]

Liang, X.H., Nichols, J.G., Hsu, C.W, Crooke, S.T. Hsc70 facilitates M6PR-mediated intracellular trafficking and enhances endosomal release of PS-ASOs. Nucleic Acid Ther. 2021. [published online ahead of print]

Liang, X.H., De Hoyos, C.L., Shen, W., Zhang, L., Fazio, M., Crooke, S.T., Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective. Nucleic Acid Therapeutics, 2021. [published online ahead of print]

Liang, X.H., Nichols, J.G., De Hoyos, C.L., Crooke, S.T. Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity. Nucleic Acids Research, 2020, 48(17):9840-9858.

Crooke, S.T., Liang, X.H., Crooke R.M., Baker, B.F., Geary, R.S. Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context. Biochemical Pharmacology 2020 ;114196. doi: 10.1016/j.bcp.2020.114196. [published online ahead of print, 2020 Aug 12]

Crooke, S.T., Seth., P.P., Vickers, T.A., Liang, X.H. The Interaction of Phosphorothioate Containing RNA Targeted Drugs with Proteins is a Critical Determinant of The Therapeutic Effects of These Agents. J. Am. Chem. Soc. 2020, 142, 35, 14754–14771

Pollak, A.J., Hickman, J.H., Liang, X.H., Crooke, S.T. Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms Nucleic Acid Ther. 2020. [published online ahead of print, 2020 Jun 23] doi/full/10.1089/nat.2020.0864.

Vickers TA, Migawa MT, Seth PP, Crooke ST. Interaction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry. J Am Chem Soc., 142:9661-9674, 2020.

Hyjek-Składanowska M, Vickers TA, Napiórkowska A, Anderson BA, Tanowitz M, Crooke ST, Liang XH, Seth PP, Nowotny M. Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins. J Am Chem Soc., 142(16):7456-7468, 2020.

Crooke, S.T., Vickers, T.A., Liang, X.H. Phosphorothioate modified oligonucleotide–protein interactions. Nucleic Acids Research, 48(10):5235–5253, 2020.

Østergaard, M.E., De Hoyos, C.L., Wan, W.B., Shen, W., Low, A., Berdeja, A., Vasquez, G., Murray, S., Migawa, M.T., Liang, X.H., Swayze, E.E., Crooke, S.T., Seth., P.P. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Research, 48(4):1691-1700, 2020.

Liang, X.H., Sun, H., Hsu, C.W., Nichols, J.G., Vickers, T.A., De Hoyos, C.L., Crooke, S.T. Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes. Nucleic Acids Research, 48(3):1372-1391, 2020.

Wang, Y., Shen, W., Liang, X.H., Crooke, S.T. Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly. Nucleic Acid Therapeutics, 29(6):343-358, 2019 epub.

Vickers, T.A., Rahdar M, Prakash, T., Crooke, S.T. Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1. Nucleic Acids Research, 47(20): 10865–10880, 2019.

Migawa, M.T., Shen, W., Wan, W.B., Vasquez, G., Oestergaard, M. E., Low, A., De Hoyos, C.L., Gupta, R., Murray, S., Tanowitz, M., bell, Melanie., Nichols, J.G., Gaus, H., Liang, X.H., Swayze, E.E., Crooke, S.T., Seth., P.P. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Research, 47(11): 5465–5479, 2019.

Wang, S., Nichols, J., Prakash, T., Liang, X.H., Crooke, S.T. Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells. Nucleic Acid Therapeutics, 29(5):245-255, 2019.

Liang, X.H., Nichols, J., Hsu, C.W., Vickers, T.A., Crooke, S.T. mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway. Nucleic Acids Research, 47(13):6900-6916, 2019.

Shen, W., Low, A., De Hoyos, C.L., Oestergaard, M. E., Wan, W.B., Vasquez, G., Bell, M., Nichols, J., Swayze, E.E., Liang, X.H., Seth, P.P., Crooke, S.T. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nature Biotechnology 640(37):640–650, 2019.

Crooke, S.T., Baker, B.F., Xia, S., Yu, R.X., Viney, N.J., Wang, Y., Tsimikas, S., Geary, R.S. Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2’-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Therapeutics, 28(1): 1-22, 2018.

Wang, S., Allen, N., Liang, X., Crooke, S.T., Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides. Molecular Therapy 13:686-698, 2018.

Liang, X.H., Sun, H., Nichols, J.G., Allen, N., Wang, S., Vickers, T.A., Shen, W., Hsu, C.W., Crooke, S.T. COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways. Nucleic Acid Res.1-21, 2018.

Crooke, S.T., Witztum, J.L., Bennett, C.F., Baker, B.F. RNA-Targeted Therapeutics. Cell Metabolism 27: 714-739, 2018.

Wang, S., Allen, N., Vickers, T.A., Revenko, A.S., Sun, H., Liang, X.H., Crooke, S.T. Cellular Uptake Mediated by Epidermal Growth Factor Receptor Facilitates the Intracellular Activity of Phosphorothioate-modified Antisens­e Oligonucleotides. Nucleic Acid Res. 46(7):3579-3594, 2018.

Shen, W., Hoyos, C.L., Sun, H., Vickers, T.A., Liang, X.H., Crooke, S.T. Acute hepatotoxicity of 2’ Fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acid Res. 46(5):2204-2217, 2018.

Liang, X.H., Nichols, J.G., Sun, H., Crooke, S.T. Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs. Nucleic Acid Res, 46(1):293-313, 2017.

Bailey, J.K., Shen, W., Liang, X., Crooke, S.T. Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides. Nucleic Acid Res 45:10647-10671, 2017.

Shen, W., Sun, H., Nichols, J., De Hoyos, C.L., Bailey, J.K., Liang, X.H., Crooke, S.T. Dynamic nucleoplasmic and nucleolar localization of mammalian RNase H1 in response to RNAP I transcriptional R-loops. Nucleic Acid Res 45:10672-10692, 2017.

Liang, X.H., Sun, H., Shen, W., Wang. S., Yao, J., Migawa, M.T., Bui, H., Damle, S.S., Riney, S., Graham, M.J., Crooke, R.M., Crooke, S.T. Antisense oligonucleotides targeting translation suppression elements in 5’ UTR can selectively increase protein levels. Nucleic Acid Res, 45(16):9528-9546, 2017.

Liang, X., Sun, H., Shen, W., Nichols, J., Crooke, S.T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol Ther 25(9):2075–2092, 2017.

Wang, S., Sun, H., Tanowitz, M., Liang, X.H., Crooke, S.T. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. Nucleic Acid Res 45:5309-5322, 2017.

Liang, X., Shen, W., Crooke, S.T. Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames. RNA Activation, Volume 983, of the series Adv Exp Med Biol, Springer Nature Singapore Pte Ltd., ed Li, Long-Cheng, 983(9):129-146, 2017.

Shen, W., Liang, X.H., Sun, H, De Hoyos, C.L., Crooke, S.T. Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation. PLoS One. 12(3):e0173494, 2017.

Crooke, S.T. Molecular Mechanisms of Antisense Oligonucleotides. Nucleic Acid Ther. 27(2):70-77, 2017.

Crooke, S.T., Wang, S., Vickers, T.A., Shen, W., Liang, X. Cellular uptake and trafficking of antisense oligonucleotides. Nature Biotech 35:230-237, 2017.

Crooke, S.T., Baker, B.F., Witztum, J.L., Kwoh, J., Pham, N.C., Salgado, N., McEvoy, B.W., Cheng, W., Hughes, S.G., Bhanot, S., Geary, R.S. The Effects of 2’-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. Nucleic Acid Ther, FastTrack Article, 2017.

Crooke, S.T., Viable RNase H1 Knockout Mice: The end of an Enigma. A layman’s review. Atlas of Science, 2016.

Liang, X.H., Shen W, Sun H, Migawa M.T., Vickers T.A., Crooke S.T. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nature Biotech 34:875-882, 2016.

van Capelleveen, J.C., Geary, R.S., Xia, S., Tami, J., Yu, R.Z., Marcovina, S.M., Hughes, S.G., Graham, M.J., Crooke, R.M., Crooke, S.T., Witztum, J.L., Stroes, E.S., Tsimikas, S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057)5-11, 2016.

Crooke, S.T., Baker, B.F., Kwoh, J., Cheng, W., Schulz, D., Xia, S., Salgado, N., Bui, H.H., Hart, C.E., Burel, S., Younis, H.S., Geary, R.S., Henry, S.P., Bhanot, S. Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers. Mol Ther 24(10):1771-1782, 2016.

Crooke, S.T., MacLeod, A.R. Antisense: Progress Towards Gene-Directed Cancer Thereapy. Reference Module in Biomedical Sciences doi: 10.1016/B978-0-12-801238-3.98738-5, 2016.

Wang, S., Sun, H., Tanowitz, M., Liang, X.H., Crooke, S.T. Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. Nucleic Acid Res 44(15):7314-30, 2016.

Vickers, T., Crooke, S.T. Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions. Plos One 11(8):e0161930, 2016.

Lima, W.F., Murray, H.M., Damle, S.S., Hart, C.E., Hung, G., De Hoyos, C. L., Liang, X.H., Crooke, S.T. Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function. Nucleic Acid Res 44(11):5299-312, 2016.

Liang, X.H., Shen, W., Sun, H., Migawa, M.T., Vickers, T.A., Crooke, S.T. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat Biotechnol 34:875-880, 2016.

Liang, X.H., Shen, W., Sun, H., Kinberger, G.A., Prakash, T.P., Nichols, J.G., Crooke, S.T. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity. Nucleic Acid Res 44(8):3892-907, 2016.

Lima, W. F., De Hoyos, C. L., Liang, X.H., Crooke, S.T. RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. Nucleic Acid Res 44(7):3351-63, 2016.

Burel, S.A., Hart, C.E., Cauntay, P., Hsiao, J., Machemer, T., Katz M., Watt, A., Bui, H. H., Younis, H., Sabripour, M., Freier, S. M., Hung, G., Dan, A., Prakash, T.P., Seth, P.P., Swayze, E.E., Bennett, C.F., Crooke, S.T., Henry, S.P. Hepatotoxicity of High Affinity Gapmer Antisense Oligonucleotides is Mediated by RNase H1 Dependent Promiscuous Reduction of Very Long pre-mRNA Transcripts. Nucleic Acid Res 18;44(5):2093-109, 2016.

Vickers, T.A., Crooke, S.T. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acid Res 43(18):8955-63, 2015.

Prakash, T.P., Lima W.F., Murray H.M., Li W., Kinberger G.A., Chappell A.E., Gaus H., Seth P.P., Bhat B., Crooke S.T., Swayze E.E. Identification of Metabolically Stable 5’-Phosphate Analogs That Support Single Stranded siRNA Activity. Nucleic Acid Res 43:2993-3001, 2015.

Shen, W., Liang, XH., Sun, H., Crooke, S.T. 2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acid Res 43(9):4569-4578, 2015.

Crooke, S.T. Health Security Preparedness and Industry Trends. Health Security 13:74-81, 2015.

Liang, X.H., Sun, H., Shen, W., Crooke, S.T. Identification and characterization of intracellular proteins that bind phosphorothioate-containing oligonucleotides. Nucleic Acid Res 43:2927-2945, 2015.

Liang, X.H., Shen, W., Crooke, S.T. Efficient and selective knockdown of small non-coding RNAs. In Methods in Molecular Biology. Humana Press, USA, Rederstorff, M. (ed) 1296:203-11, 2015.

Geary, R., Baker, B., Crooke, S.T. Clinical and Preclinical Pharmacokinetics And Pharmacodynamics Of Mipomersen (KYNAMRO®), A Second Generation Antisense Oligonucleotide Inhibitor Of Apolipoprotein B. Clinical Pharmacokinet 54:133-146, 2015.

Vickers, T.A., Freier S.M., Bui, H.H., Watt, A., Crooke, S.T. Targeting of repeated sequences unique to a gene results in significant increases antisense oligonucleotide potency. PLos One 9(10):e110615, 2014.

Vickers, T., Crooke, S.T. Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLos One 9(10):e108625, 2014.

Lima, W., Vickers, T., Nichols, J., Li, C., Crooke, S.T. Defining the factors that contribute to on-target specificity for antisense oligonucleotides. PLos One (7)9:e101752, 2014.

Liang, X.H., Shen, W., Sun, H., Prakash, T.P., Crooke, S.T. TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acid Res 42:7819-7832, 2014.

Shen, W., Liang, X.H., Crooke, S.T. Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structure. Nucleic Acid Res 14:8648-8662, 2014.

Liang, X.H., Crooke, S.T. RNA helicase A is not required for RISC activity. BBA – Gene Regulatory Mechanisms 1829:1092–1101, 2013.

Wu, H., Sun, H., Liang, X.H., Lima, W.F., Crooke, S.T. Human RNase H1 is associated with protein P32 and is involved in mitrochondrial pre-rRNA processing. PLos One 8(8):e71006, 2013.

Prakash, T.P., Lima, W.F., Murray, H.M., Elbashir, S., Cantley, W., Foster, D., Jayaraman, M., Chappell, A.E., Manoharan, M., Swayze, E.E, Crooke, S.T. Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals. ACS Chem Biol 8:1402-6, 2013.

Graham, M.J. Richard, G.L., Bell, T.A., Fu, W., Mullick, A.E., Alexander, V.J., Singleton, W.S, Viney, N., Geary, R.S., Su, J., Baker, B.F., Burkey, J., Crooke, S.T., Crooke, R.M. Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates and Man. Circulation Res 112:1479-1490, 2013.

Crooke, S.T. RNA Directed Therapeutics: Mechanisms and Status. Drug Disc Today: Thera Strat 10:e109-e117, 2013.

Liang, XH., Hart, C.H., Crooke, S.T. Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochim Biophys Acta 1829:455-468, 2013.

Crooke, S.T., Geary, R.S. Clinical pharmacological properties of mipomersen (Kynamro), a second-generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 76:269–276, 2013.

Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H.B., Cleveland, D.W., Swayze E.E., Lima, W.F., Crooke S.T., Prakashm, T.P., Corey, D.R. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150:895-908, 2012.

Lima, W., Prakash, T.P, Murray, H.M., Kinberger, G.A., Li, W., Chappell, A.E., Li, C.S., Murray, S.F., Gaus, H., Seth, P.P., Swayze, E.E., Crooke, S.T. Single-stranded siRNAs Activate RNAi in Animals. Cell 150:883-894, 2012.

Liang, XH., Vickers, T., Crooke, S.T. Antisense-mediated reduction of eukaryotic non-coding RNAs. In Nucleic Acids Sequences to Molecular Medicine by Erdmann, V.A. and Barciszewski, J. (eds), Heidelberg, Springer-Verlag, Chapter 11, 2011.

Vickers, T., Crooke, S.T. siRNAs targeted to certain polyadenylation signals promote specific, RISC-independent degradation of messenger RNAs. Nucleic Acid Res 40:1-12, 2011.

Crooke, S.T. Renovation of the New Medicine Regulatory Process. Clinical Research and Regulatory Affairs, 81-86, December 2011.

Crooke, S.T. The Isis Manifesto/Isis: Creating a New Platform for Drug Discovery. Nature Bioentrepreneur. 1-6, 2011.

Vickers, T.A., Sabripour, M., Crooke, S.T. U1 Adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Research 39(10):e71, 2011.

Liang, X.H., Crooke, S.T. Depletion of key portein componets of the RISC pathway impairs pre-ribosomal RNA processing. Nucleic Acids Research 39:4875-4889, 2011.

Liang, X.H., Vickers, T.A., Guo, S., Crooke, S.T. Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. Nucleic Acids Research 39:1-17, 2011.

Raal, F.J. Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., Tribble, D.L., Flaim, J.D., Crooke, S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998-1006, 2010.

Vickers, T.A., Lima, W.F., Wu, H., Nichols, J.G., Linsley, P.S., Crooke, S.T. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 ‘Slicer’ independent and can be mediated by Ago1. Nucleic Acids Research 37:6927-6941, 2009.

Lima, W.F., Wu, H., Sun, H., Murray, H.M., Crooke, S.T. Binding and Cleavage Specificities of Human Argonaute2. J Biol Chem 284:25653-25663, 2009.

Lima, W.F. Murray, H., Nichols, J.G., Wu, H., Sun, H., Prakash, T.P., Berdeja, A.R., Gaus, H.J., Crooke, S.T. Human Dicer binds short single-strand and double-strand RNA with high affinity and interacts with different regions of the nucleic acids. J Biol Chem 284:2535-2548, 2009.

Lima, W.F., Wu, H., Crooke, S.T. The RNase H Mechanism. In Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition, Crooke, ST. (ed) Baco Raton, FL, Chapter 2, 47-74, 2008.

Crooke, S.T., Vickers, T., Lima, W.F., Wu, H. Mechanisms of Antisense Drug Action, an Introduction. In Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition, Crooke, ST. (ed), Baco Raton, FL, CRC Press, Chapter 1, 3-46, 2008.

Vickers, T., Lima, W.F., Nichols, J.G., Crooke, S.T. Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Research 35:6598-610, 2007.

Graham, M.J., Lemonidis, K.M., Whipple, C.P., Subramaniam, A., Monia, B.P., Crooke, S.T., Crooke, R.M. Inhibition of Proprotein Convertase Subtilisin Kexin 9 with a Second Generation Antisense Inhibitor Reduces Serum LDL-C in Hyperlipidemic Mice. J Lipid Research 48:763-767, 2007.

Lima, W.F. Rose, J.B., Nichols, J.G., Wu, H., Migawa, M.T., Wyrzykiewicz, T.K., Siwkowski, A.M., Crooke S.T. Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol 71:83-91, 2007.

Lima, W.F., Rose, J.B., Nichols, J.G., Wu, H., Migawa, M.T., Wyrzykiewicz, T.K., Vasquez, G., Swayze E.E., Crooke, S.T. The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol Pharmacol 71:73-82, 2007.

Ecker, D.J., Sampath, R., Blyn, L.B., Eshoo, M.W., Ivy, C., Ecker, J.A., Libby, B., Samant, V., Sannes-Lowery, K.A., Melton, R.E., Russell, K., Freed, N., Barrozo, C., Wu, J., Rudnick, K., Desai, A., Moradi, E., Knize, D.J., Robbins, D.W., Hannis, J.C., Harrell, P.M., Massire, C., Hall, T.A., Jiang, Y., Ranken, R., Drader, J.J., White, N., McNeil, J.A., Crooke, S.T., Hofstadler, S.A. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. Proc Natl Acad Sci 102(22):8012-8017, 2005.

Sampath, R., Hofstadler, S.A., Blyn, L.B., Eshoo, M.W., Hall, T.A., Massire, C., Levene, H.M., Hannis, J.C., Harrell, P.M., Neuman, B., Buchmeier, M.J., Jiang, Y., Ranken, R., Drader, J.J., Samant, V., Griffey, R.H., McNeil, J.A., Crooke, S.T., Ecker, D.J. Rapid identification of emerging pathogens: coronavirus. Emerg Infect Dis 11(3):373-379. 2005.

Lima, W.F. Nichols, J.G., Wu, H., Prakash, T.P., Migawa, M.T., Wyrzykiewicz, T.K., Bhat, B., Crooke, S.T. The structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J Biol Chem 279:36317-36326, 2004.

Crooke, S.T. Antisense Strategies. Current Molecular Medicine 4:465-487, 2004.

Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H., Crooke, S.T. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs. J Biol Chem 279:17181-9, 2004.

Crooke, S.T. Progress in Antisense Technology. Annual Review of Medicine 55:61-95, 2004.

Lima, W.F., Wu, H., Nichols, J.G., Prakash, T.P., Ravikumar, V., Crooke, S.T. Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3’-DNA/5’-RNA terminus of the heteroduplex substrate. J Biol Chem 278:49860-49867, 2003.

Crooke, S.T. Progress in Antisense Technology. In Cancer Drug Discovery: Drug Delivery Systems for Cancer. Teicher, B. (ed), Brown, D.M. (sect ed), Humana Press, Totowa, NJ, 2004.

Crooke, S.T. Antisense Therapy. In the Cytokine Handbook 4th Edition, Chapter 60. Thomson, A. and Lotze, M.T. (eds), Academic Press, London, UK, 2003.

Lima, W.F., Wu, H, Nichols, J.G., Manalili S.M., Drader J.J., Hofstadler S.A., Crooke S.T. Human RNase H1 activity is regulated by a unique redox switch formed between adjacent cysteines. J Biol Chem 278:14906-14912, 2003.

Crooke, S.T. Oligonucletide Therapeutics. In Burger’s Med Chem Drug Disc 6th Edition, Vol 2, Chapter 5, 115-166, 2003.

Vickers, T.A., Koo, S., Bennett, C.F., Crooke, S.T., Dean, N.M., Baker, B.F. Efficient Reduction of Target RNAs by siRNA and RNase H-Dependent Antisense Agents: A Comparative Analysis. J Biol Chem 278:7108-7118, 2003.

Crooke, S.T. Antisense: Progress toward Gene-Directed Cancer Therapy. Encyclopedia of Cancer, Second Edition, 1:127-134, 2002.

Crooke, S.T., Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. American J. Ophthalmology, 133:4, 467-474, 2002

Crooke, S.T., Vitravene Study Group. Randomized Dose-comparison Studies of Intravitreous Fomivirsen for Treatmentof Cytomegalovirus Retinitis That Has Reactivated or Is Persistently Active Despite Other Therapies in Patients With AIDS. American J. Ophthalmology, 133:4, 475-483, 2002

Crooke, S.T., Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. American J. Ophthalmology, 133:4, 484-498, 2002

Crooke, S.T. Pharmaceutical Biotechnology, Editorial Overview. Curr Opin in Biotech 12:605-606, 2001.

Graham, M.J., Crooke, S.T., Lemonidis, K.M, Gaus, H.J., Templin, M.V., Crooke, R.M. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol 62:297-306, 2001.

Crooke, S.T. Antisense: Progress toward gene-directed cancer therapy, In Biotechnology International, B. Alizadeh (ed) Universal Medical Press, Inc, San Francisco, CA, 1-6, 2001.

Yacyshyn, B.R., Crooke, S.T. The Concept and Application of Antisense Oligonucleotide. Diseases of the Colon and Rectum 44:1241-1243, 2001.

Crooke, S.T. Basic Principles of Antisense Technology. Antisense Drug Technology: Principles, Strategies and Applications, Crooke, S.T. (ed), Marcel Dekker, Inc., New York, NY, Ch 1, 1-28, 2001.

Lima, W.F., Crooke, S.T. Human RNase H. Methods Enzymol 341:430-440, 2001.

Lima, W.F., Crooke, S.T. Preparation and use of ZFY-6 Zinc Finger Ribonuclease. Methods Enzymol 341:490-500, 2001.

Wu, H., Xu, H., Lima, W.F., Crooke, S.T. Investigating the structure of human RNase H1 by site-directed mutagenesis. J Biol Chem 276:23547-23553, 2001.

Crooke, S.T. Potential roles of antisense technology in cancer chemotherapy. Oncogene 19:6651-6659, 2000.

Wu, H., Xu, H., Miraglia, L.J., Crooke, S.T. Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem 275:36957-36965, 2000.

Miraglia, L., Watt, A.T., Graham, M.J., Crooke, S.T. Variations in mRNA content have no effect on the potency of antisense oligonucleotides. Antisense and Nuc Acid Drug Dev 10:453-461, 2000.

Crooke, S.T. Oligonucleotide-based drugs in the control of cytokine synthesis. In Novel Cytokine Inhibitors, Higgs, G.A. and Henderson, B. (eds) Birkhäuser Verlag, Basel, Switzerland, 83-101, 2000.

Crooke, S.T. Letter to the Editor: Comments on evaluation of antisense drugs in the clinic. Antisense and Nuc Acid Drug Dev 10:225-227, 2000.

Crooke, S.T. Commentary: Evaluating the mechanism of action of anit-proliferative antisense drugs. Antisense and Nuc Acid Drug Dev 10:123-126, 2000.

Crooke, S.T. Progress in antisense technology: The end of the beginning. In Methods in Enzymology – Antisense Therapeutics, Phillips, M.I. (ed) Academic Press, New York, NY, 313:3-45, 1999.

Crooke, S.T. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489:30-42, 1999.

Crooke, S.T. Molecular Mechanisms of Antisense Drugs: Human RNase H’s. Antisense and Nuc Acid Drug Dev 9:377-379, 1999.

Griffey, R.H., Hofstadler, S.A., Sannes-Lowery, K.A., Ecker, D.J., Crooke, S.T. Determinants of Aminoglycoside binding specificity for rRNA using mass spectrometry. Proc Natl Acad Sci 96:10129-10133, 1999.

Crooke, S.T. Genotypic drug discovery: what does the future hold? Pharmaceutical Science and Technology Today. Supplement 10-11, 1999.

Wu, H., Lima, W.F., Crooke, S.T. Properties of cloned and expressed Human RNase H. J Biol Chem 274:28270-28278, 1999.

Lima, W.F., Crooke, S.T. Highly efficient endonucleolytic cleavage of RNA by a Cys2His2Zinc finger peptide. Proc Natl Acad Sci 96:10010-10015, 1999.

Hofstadler, S.A., Sannes-Lowery, K.A., Crooke, S.T., Ecker, D.J., Sasmor, H., Manalili, S., Griffey, R.H. Multiplexed screening of neutral mass tagged RNa targets against ligand libraries with electrospray ionization FT-ICR MS: A new paradigm for high-throughput affinity screening. J Biol Chem 71:3436-3440, 1999.

Crooke, S.T. Antisense Oligonucleotides. In Encyclopedia of Molecular Biology. Creighton, T.E. (ed), John Wiley & Sons, New York, NY, 169-172, 1999.

Crooke, S.T. Review of: Advances in drug discovery techniques, Harvey, A. (ed), Chemistry & Industry 6:230, 1999.

Crooke, S.T. Antisense Therapeutics in Biotechnology & Safety Assessment, Second Edition, Thomas, J.A. (ed), Taylor & Francis, Philadelphia, 2:23-60, 1999.

Crooke, S.T. Antisense Therapeutics In Biotechnology & Genetic Engineering Reviews, Chapter 5, Tombs, M.P. (ed), Intercept Ltd, Andover, England, 121-157, 1998.

Levesque, L., Crooke, S.T. Depletion of Protein Kinase C-a by antisense oligonucleotides alters beta-adrenergic function and reverses the phorbol ester-induced reduction of isoproterenol-induced cAMP accumulation in murine Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 287:425-434, 1998.

Crooke, S.T. VitraveneTM – Another Piece in the Mosaic. Antisense and Nuc Acid Drug Dev 8:vii-viii, 1998.

Graham, M.J., Crooke, S.T., Monteith, D.K., Cooper, S.R., Lemonidis, K.M., Stecker, K.K, Martin, M.J., Crooke, R.M. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458, 1998.

Crooke, S.T., Bennett, F.C., Door, R.A. Antisense 98: Work in progress. Nature Biotechnology 16:1319-1321, 1998.

Crooke, S.T. Optimizing the impact of genomics on drug discovery and development. Nature Biotech (16) Supplement 29-30, 1998.

Crooke, S.T. Treatment of retinitis induced by cytomegalivirus using intravitreal fomivirsen (ISIS 2922). In Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, E. Wickstrom (ed), Marcel Dekker, Inc., New York, NY, 18:353-361, 1998.

Crooke, S.T. Basic Principles of Antisense Therapeutics. In Antisense Research and Application. Handbook of Experimental Pharmacology, S. T. Crooke (ed), Springer-Verlag, Berlin Heidelberg, 131, 1-50, 1998.

Crooke, S.T. Molecular mechanisms of antisense drugs: RNase H. Antisense and Nuc Acid Drug Dev 8:133-134, 1998.

Crooke, S.T. An overview of progress in antisense therapeutics. Antisense and Nuc Acid Drug Dev 8:115-122, 1998.

Wu, H., Lima, W.F., Crooke, S.T. Molecular cloning and expression of cDNA for human RNase H. Antisense and Nuc Acid Drug Dev 8:53-61, 1998.

Wu, H., MacLeod, R., Lima, W.F., Crooke, S.T. Identification and partial purification of human double-strand RNase activity: a novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem 273:2532-2542, 1998.

Crooke, S.T. Antisense Oligonucleotides. European BioPharmaceutical Review 42-50, 1997.

Crooke, S.T. Progress in Antisense Therapeutics Discovery and Development. Oligonucleotides as Therapeutic Agents. Ciba Foundation Symposium 209, 158-168, 1997.

Manoharan, M., Tivel, K.L., Condon, T.P., Andrade, L.K., Barber-Peoch, I., Inamati, G., Shah, S., Mohan, V., Graham, M.J., Bennett, C.F., Crooke, S.T., Cook P.D. Conjugated antisense oligonucleotides. Nucleosides & Nucleotides 16:1129-1138, 1997.

Lima, W.F., Crooke, S.T. Cleavage of single-strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J Biol Chem 272:27513-27516, 1997.

Crooke, S.T. Advances in understanding the pharmacological properties of antisense oligonucleotides. Antisense Oligodeoxynucleotides and Antisense RNA. CRC Press LLC, Baca Raton, 17-55, 1997.

Crooke, S.T. In Anti-Cancer Drug Design- Special Issue. S.T. Crooke (ed), Oxford University Press, United Kingdom, 1997.

Crooke, S.T. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv Pharmacol 40:1-49, 1997.

Levesque, L., Dean, N.M., Sasmor, H., Crooke, S.T. Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol Pharmacol 51:209-216, 1997.

Lima, W.F., Mohan, V., Crooke, S.T. The influence of antisense oligonucleotide-induced RNA structure on E. coli RNase H1 activity. J Biol Chem 272:18191-18199, 1997.

Lima, W.F., Crooke, S.T. Binding affinity and specificity of Escherichia coli RNase H1: Impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36:390-398, 1997.

Henry, S.P., Zuckerman, J.E., Rojko J., Hall, W.C., Harman, R.J., Kitchen D., Crooke ST.. Toxicological properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Design 12:1-14, 1997.

Crooke, S.T. Antisense oligonucleotides. In Cancer Therapeutics: Experimental and Clinical Agents, 229-335, B.A. Teicher (ed). Humana Press, Inc., Totowa, NJ, 1997.

Crooke, S.T., Bernstein, L.S., Boswell, H. Biologicals and Immunologicals: Progress in the development and patenting of antisense drug discovery technology. Exp Opin Ther Patents 6:855-870, 1996.

Crooke, R.M., Crooke, S.T., Graham, J.J., Cooke, M.E. Effect of antisense Oligonucleotides on Cytokine Release from Human Keratinocytes in an In vitro Model of Skin. Toxicol Appl Pharmacol 140:85-93, l996.

Crooke, S.T. Commentary: Proof of mechanism of antisense drugs. Antisense Nuc. Acid Drug Dev 6:145-147, 1996.

Crooke, S.T. Monthly Update: Biologicals and Immunologicals. Progress in the development of antisense drugs. Exp Opin Invest Drug 5:1047-1052, 1996.

Bennett, C.F., Zuckerman, J.E., Kornbrust, D., Sasmor, H., Leeds, J.M., Crooke, S.T. Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Control Rel 41:121-130, 1996.

Crooke, S.T. Progress in antisense therapeutics. Med Res Rev 16:319-344, 1996.

Crooke, S.T. et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923-937, 1996.

Crooke, S.T., Bennett, C.F. Progress in antisense oligonucleotide therapeutics. Ann Rev Pharmacol Toxicol 36:107-129, 1996.

Crooke, S.T. New drugs and changing disease paradigms. Nature Biotech 14:238-241, 1996.

Crooke, S.T. Therapeutic applications of oligonucleotides in medicine. Chem Ind 90-93, 1996.

Crooke, S.T. Editorial: The future of sequence-specific transcriptional inhibition. Cancer Invest 4:89-90, 1996.

Bennett, C.F., Crooke, S.T. Oligonucleotide-based inhibitors of cytokine expression and function. “Therapeutic Modulation of Cytokines” a volume in: Pharmacology and Toxicology: Basic and Clinical Aspects, 171-193, Henderson, B., and Bodmer, M.W. (eds), CRC Press, Boca Raton, FL, 1996.

Crooke, S.T. Antisense Therapeutics. In Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s, Cuello, A.C. and Collier. B. (eds), Birkhäuser Verlag Basel, Switzerland, 393-399, 1995.

Crooke, S.T. et al. Kinetic characteristics of E. coli RNase H1: Cleavage of various antisense oligonucleotides-RNA duplexes. Biochem J 312:599-608, 1995.

Hodges, D., Crooke, S.T. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol Pharm 48:905-918, 1995.

Crooke, S.T. The future of antisense technology. Pharmaceutical News 2:8-11, 1995.

Crooke, R.M., Graham, M.J., Cooke, M.E., Crooke S.T. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462-473, 1995.

Crooke, S.T. Editorial: Delivery of oligonucleotides and polynucleotides. Drug Targeting 3:185-190, 1995.

Crooke, S.T. Redefining the biotech industry. Biocentury 3:A1-A6, 1995.

Crooke, S.T. Progress in antisense therapeutics. Hematol Pathol 9:59-72, 1995.

Ecker, D.J., Crooke, S.T. Combinatorial drug discovery: Which methods will produce the greatest value? BioTechnology 13:351-360, 1995.

Crooke, S.T. Oligonucleotide Therapeutics. In Burger’s Medicinal Chemistry and Drug Discovery, Vol 1: Principles and Practice, 863-900, Manfred E. Wolff, (ed), John Wiley & Sons, Inc, 1995.

Crooke, S.T. Comprehensive reform of the new drug regulatory process. BioTechnology 13:25-29, 1995.

Crooke, S.T. The Isis Strategy to Exploit a Broadly Enabling Technology: Antisense. Proceedings of Bio-Japan, 1994.

Crooke, S.T. et al. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharm Therap 56:641-646, 1994.

Crooke, S.T. Guest Editorial: Progress in evaluation of the potential of antisense technology. Antisense Res Dev 4:145-146, 1994.

Bennett, C.F., Crooke, S.T. Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides. Adv Pharmacol 28:1-43, 1994.

Cossum, P.A., Truong, L., Owens, S.R., Markham, P.M., Shea, J.P., Crooke, S.T. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89-94, 1994.

Cossum, P.A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S.R., Markham, P.M., Shea, J.P., Crooke S.T. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190, 1993.

Crooke, S.T. Commentary: Regulatory issues affecting oligonucleotides. Antisense Res Dev 3:301-306, 1993.

Crooke, S.T. Therapeutic Potential of Oligonucleotides. Curr Opin Invest Drugs 2:1045-1048, 1993

Perlaky, L., Saijo, Y., Busch, R.K., Bennett, C.F., Mirabelli, C.K., Crooke, S.T., Busch. H. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Design 8:3-14, 1993.

Mirabelli, C.K., Crooke, S.T. Antisense oligonucleotides in the context of modern molecular drug discovery and development. In: Antisense Research and Applications, 7-35, Crooke, S.T., Lebleu, B. (eds), CRC Press, Boca Raton, FL, 1993.

Crooke, S.T. Guest Editorial: Oligonucleotide therapeutics: A prospectus. Antisense Res Dev 3:1-2, 1993.

Crooke, S.T. Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB 7:533-539, 1993.

Bennett, C.F., Chiang, M.Y., Monia, B.P., Crooke, S.T. Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. Biochem J 289:33-39, 1993.

Crooke, S.T. Oligonucleotide therapy. Current Opin Biotechnol 3:656-661, 1992.

Crooke, S.T. Review: Therapeutic applications of oligonucleotides. Biotechnology 10:882-886, 1992.

Wong, A. et al. Stimulation of Leukotriene Production and Membrane Translocation of 5-Lipoxygenase by Cross-linking of the IG Receptors in RBL-2H3 Cells. Biochemistry 31:4046-4053, 1992.

Crooke, S.T., Mirabelli, C.K. Application of oligonucleotide drugs for cancer prevention. In Mol Targets Cancer Chemoprev, 83-92, VE Steele (ed), CRC Press, Boca Raton, FL, 1992.

Crooke, S.T. Nucleic acid therapeutics. Pharmaceutical Manufacturing International 89-93, 1992.

Crooke, S.T. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376, 1992.

Tan, K.B. et al. Topoisomerase lla and IIb Genes: Characterization and Mapping to Human Chromosomes 17 and 3, Respectively. Cancer Res 52:231-234, 1992.

Mirabelli, C.K., Bennett, C.F., Anderson, K. and Crooke, S.T. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Design 6:647-661, 1991.

Crooke, S.T., Monia, B.P., Chiang, M.Y. and Bennett, C.F. Leukotriene receptors and mechanisms of signal transduction. Ann NY Acad Sci 629:120-124, 1991.

Clark, M.A. et al. Cloning of a phospholipase A2-activating protein. Proc Natl Acad Sci USA 88:5418-5422, 1991.

Crooke, S.T. Antisense technology. Curr Opin Biotechnol 2:282-287, 1991.

Sanghvi, Y.S. et al. Synthesis and biological evaluation of antisense oligonucleotides containing modified pyrimidines. Nucleosides Nucleotides 10:345-346, 1991.

Guinosso, C.J. et al. Synthesis and biophysical and biological evaluation of 2′-modified antisense oligonucleotides. Nucleosides Nucleotides 10:259-262, 1991.

Wong, A., Crooke, S.T. Regulation of 5-lipoxygenase activity in rat basophilic leukemia cells. In Lipoxygenases and Their Products, 67-87, Crooke, S.T., Wong, A. (eds), Academic Press, Inc, San Diego, CA, 1991.

Crooke, S.T. Antisense Technology. Curr Opin Biotechnol 2:282-287, 1991.

Mattern, M.R., Nambi P., Bartus, J.O., Mirabelli, C.K., Crooke, S.T., Johnson, R.K. Regulation Topoisomerase I and II Activities by Cyclic Nucleotide and Phospholipid Dependent Protein Kinases. Receptor 1:181-190, 1991.

Bennett, C.F., Angioli, M.P., Crooke, S.T. Purification of Guinea Pig Uterus Phosphoinositide- Specific Phospholipase C. Methods Enzymol, Vol 197, 526-535, 1991.

Mirabelli, C.K. et al. Topoisomerase Heterogeneity: Implications for the Discovery of Novel Antitumor Drugs. In First International Conference on Topoisomerase in Cancer Chemotherapy, (Potmesil, M., Kohn, K.W. (eds) London, Oxford University Press 33:2963-2970, 1990.

Bomalaski, J.S., Fallon, M., Turner, R.A., Crooke, S.T., Meunier, P.C., Clark, M.A. Identification and Isolation of a Phospholipase A2 Activating Protein in Human Rheumatoid Synovial Fluid: Induction of Eicosanoid Synthesis and an Inflammatory Response in Joints Injected In Vivo. J Lab Clin Med 116:814-825, 1990.

Clark, M.A., Conway, T.M., Cook, M., Webb, L., Dispoto, J., Mong, S., Short, R., Steiner, S., Littlejohn, D., Crooke, S.T. Inhibition of Leukotriene D4 Mediated Release of Prostacyclin Using Antisense DNA. In Biology of Cellular Transducing Signal, J.Y. Vanderhoek, (ed), 381-390, Plenum Press, 1990.

Winkler, J.D., Sarau, H.M., Foley, J.J., Crooke, S.T. Inhibitors of Protein Kinase C Selectively Enhanced Leukotriene D4-lnduced Calcium Mobilization in Differentiated U-937 Cells. Cellular Signaling 2:427-437, 1990.

Sarau, H.M., Tzimas, M.N., Foley, J.J, Winkler, J.D., Kennedy, M.E., Crooke, S.T. Leukotriene D4 Increases the Metabolism of an Inositol Tetrakisphosphate – Containing Phospholipid in U937 Cells. In Biology of Cellular Transducing Signals, Vanderhoek, J.Y. (ed), 235-243, Plenum Press, 1990.

Aiyar, N., Nambi, P., Crooke, S.T. Desensitization of Vasopression Sensitive Adenylate Cyclase by Vasopressin and Phorbolesters. Cellular Signaling 2:153-160, 1990.

Bennett, C.F., McCarte, A., Crooke, S.T. Purification and Characterization of a Soluble Phospholipase A2 from Guinea Pig Lung. Biochim Biophys Acta 1047:271-283, 1990.

Clark, M.A., Bomalaski, J.S., Conway, T.M., Cook, M., Dispoto, J., Mong, S., Shorn, R.G.L., Stadell, J., Webb, L., Crooke, S.T. The Role of Phospholipase A2 Activating Protein (PLAP) in Regulating Prostanoid Production in Smooth Muscle and Endothelial Cells Following Leukotriene D4 Treatment. In Phospholipase A, Wong, P.Y.K., Dennis, E.A. (eds), 125-144, Plenum Press, New York, NY, 1990.

Nakada, M.T., Stadel, J.M., Crooke, S.T. Mobilization of Extracellular Ca2+ by Prostaglandin F2, Can Be Modulated by Fluoride in 3T3-L1 Fibroblasts. Biochem J 272:167-174, 1990.

Monia, B.P., Ecker, D.J., Finley, D., Crooke, S.T. A Human Ubiquitin Carboxyl Extension Protein Functions in Yeast. J Biol Chem 265:19356-10361, 1990.

Winkler, J.D., Sarau, H.M., Foley, J.J., Crooke, S.T. Inhibitors of Protein Kinase C Selectively Enhanced Leukotriene D4-Induced Calcium Mobilization in Differentiated U-937 Cells. Cellular Signaling 2:427-437, 1990.

Crooke, S.T, Sarau, H., Saussy, D., Winkler, J., Foley, J. Signal Transduction Processes for the LTD4 Receptor. In Advances in Prostaglandin Thromboxane and Leukotriene Research, Vol. 20, Samuelsson, B. et al, (eds.), 127-137, Raven Press, Ltd, NY, 1990.

Crooke, S.T. et al. Studies on the Structure and Function of Ubiquitin. In Protein Design and the Development of New Therapeutics and Vaccines, Hook J.B. and Poste, G. (eds), 425-447, Plenum Publishing Corporation, 1990.

Nakada, M.T., Stadel, J.M., Crooke, S.T. Subtyped Selective Regulation of Adrenergic Receptor-Adenylyl Cyclase Coupling by Phorbol Ester in 3Y3-L1 Fibroblasts. J Pharmacol Exp Ther 253:221-229, 1990.

Monia, B.P., Ecker, D.J., Crooke, S.T. New Perspectives on the Structure and Function of Ubiquitin. Biotechnology 8:209-215, 1990.

Cruz-Rivera, M., Bennett, C.F., Crooke, S.T. Glycerol-3-Phospho-Myo-lnositol-4 Phosphate (GRO-61P) is an Inhibitor of Phosphoinositide-Specific Phospholipase C. Biochim Biophys Acta 1042:113-118, 1990.

Crooke, S.T. The Role of Research and Development in the Creation and Implementation of Corporate Strategy. Handbook of Business Strategy, 1989/1990 Yearbook, Harold E. Glass, (ed), Chapter 21, 1-21, 1990.

Mattern, M.R., Mong, S., Mong, S.M., Bartus, J.O., Sarau, H.M., Clark, M.A., Foley, J.J, Crooke, S.T. Transient Activation of Topoisomerase I in LTD4 Signal Transduction in Human Cells. Biochem J 265:101-107, 1990.

Nambi, P., Mattem, M., O’Leary-Bartus, J., Aiyar, N., Crooke, S.T. Stimulation of Intercellular Topoisomerase I Activity by Vasopressin and Thrombin, Differential Regulation by Pertussis Toxin. Biochem J 262:485-489, 1989.

Kanaho, Y., Katada, T., Hoyle, K., Crooke, S.T., Stadel, J.M. Immunochemical Comparison of Pertussis Toxin Substrates in Brain and Peripheral Tissues. Cellular Signaling 1:553-560, 1989.

Nambi, P., Aiyar, N., Whitman, M., Grier, C.E., Crooke, S.T. Homologous and Heterologous Desensitization Mediated by Vasopressin in Smooth Muscle Cells. Cellular Signaling 1:241-251, 1989.

Saussy, D.L., Sarau, H.M., Foley, J.J., Mong, S., Crooke, S.T. Mechanisms of Leukotriene E4 Partial Agonist Activity at Leukotriene D4 Receptors in Differentiated U-937 Cells. J Biol Chem 64:19845-19855, 1989.

Chung, T.D., Drake, F.H., Tan, K.B., Per, S.R., Crooke, S.T., Mirabelli, C.K. Characterization and Immunological Identification of cDNA Clones Encoding Two Human DNA Topoisomerase II Isozymes. Proc Natl Acad Sci USA 86:9431-9435, 1989.

Drake, F.H., Zimmerman, J.P., McCabe, F.L., Bartus, H.F., Per, S.R., Sullivan, D.M., Ross, W.E., Mattern, M.R., Johnson, R.K., Crooke, S.T., Mirabelli, C.K. Biochemical and Pharmacological Properties of pl 70 and p180 Forms of Topoisomerase II. Biochemistry 28:8154-8160, 1989.

Mattern M.R., Tan, K.B., Zimmerman, J.P., Mong, S.M., Bartus, J.O., Hofmann, G.A., Drake, F.H., Johnson, R.K., Crooke, S.T., Mirabelli, C.K. Evidence for the Participation of Topoisomerases I and 11 in Cadmium-induced Metallothionein Expression in CHO Cells. Anti Cancer Drug Design 4:107-124, 1989.

Monia, B.P., Haskell, K.M., Ecker, J.R., Ecker, D.J., Crooke, S.T. Chromosomal Mapping of the Ubiquitin Gene Family in SaccharaomYces Cerevisiae by Pulsed Field Gel Electrophoresis. Nucleic Acids Research 17:3611-3612, 1989.

Nambi, P., Watt, R., Whitman, M., Aiyar, N., Moore, J.P., Evan, G.I., Crooke, S.T. Induction of c-for Protein by Activation of Vasopressin Receptors in Smooth Muscle Cells. FEBS Lett 245:61-64, 1989.

Nambi, P., Mattem, M.R., O’Leary-Bartus, J., Aiyar, N. and Crooke, S.T. Stimulation of Intracellular Topoisomerase I Activity by Vasopressin and Thrombin. Differential Regulation by Pertussis Toxin. Biochem J 262:485-489, 1989.

Drake, F.H. et al. In vitro and Intracellular Inhibition of Topoisomerase II by the Antitumor Agent Merbarone. Cancer Res 49:2578-2583, 1989.

Tan, K.B., Grillone, L., Boyce, R., Crooke, S.T. Altered Actin and Immunoglobulin Cu Expression in Nitrogen Mustard-Resistant Human Burkitt Lymphoma Cells. J Cell. Biochem 40:407-415, 1989.

Aiyar, N. et al. Solubilization of Rat Liver Vasopressin Receptors as a Complex with a Guanine Nucleotide Binding Protein and Phosphoinositide-Specific Phospholipase C. Biochem J 261:63-70, 1989.

Crooke, S.T., Bennett, C.F. Mammalian Phosphoinositide-Specific Phospholipase Isoenzymes. Cell Calcium 10:309-323, 1989.

Jonnalagadda, S., Butt, T.R., Monia, B.P., Mirabelli, C.K., Gotlib, L., Ecker, D.J., Crooke, S.T. Multiple (2-NH-Ubiquitin) Protein Endoproteases in Cells. J Biol Chem 264:10637-10642, 1989.

Monia, B.P. Ecker, D.J., Jonnalagadda, S., Marsh., J., Gotlib, Butt, T.R., Crooke, S.T. Gene Synthesis, Expression and Processing of Human Ubiquitin Carboxyl Extension Proteins. J Biol Chem 264:4093-4103, 1989.

Nakada, M.T., Haskell, K.M., Ecker, D.J., Stadel, J.M., Crooke, S.T. Genetic Regulation of B2-Adrenergic Receptors in 3T3-L1 Fibroblasts. Biochem J 260:53-59, 1989.

Kanaho, Y., Crooke, S.T., Stadel, J. Purification and Characterization of Predominant Protein from Bovine Lung Membranes: Biochemical and Immunochemical Comparison with Gi and Go Purified from Brain. Biochem J 259:499-506, 1989.

Ecker, D.J. et al. Increasing Gene Expression in Yeast by Fusionto Ubiquitin. J Biol Chem 264:7715-7719, 1989.

Crier, C.E., Nambi, P., Aiyar, N., Crooke, S.T. Molecular Mechanisms of Homologous and Heterologous Desensitization Mediated by Vasopressin in Smooth Muscle Cells. J Biol Chem 264:5384-5391, 1989.

Ecker, D.J., Butt, T.R., Crooke, S.T. Yeast Metallothionein: Gene Function and Regulation by Metal ions. Metal Ions in Biological Systems 25:147-169, 1989.

Butt, T.R., Jonnalagadda S., Monia, B.P., Sternberg, E.J., Marsh, J.A., Stadel, J.M., Ecker, D.J., Crooke, S.T. Ubiquitin Fusion Augments the Yield of Cloned Gene Products in Escherichia coli. Proc Natl Acad Sci USA 86:2540-2544, 1989.

Crooke, S.T. et al. The Signal Transduction System of the Leuketriene D4 Receptor. Trends Phamacol Sci 10:103-107, 1989.

Stadel, J.M., Crooke, S.T. Fluoride Interaction with G-Proteins. Biochem J 258:932-933, 1989.

Nambi, P., Whitman, M., Aiyar, N., Stassen, F., Crooke, S.T. Inhibition of Atrial Natriuretk Factor-lnduced cGMP Accumulation by Phorbol Dibutyrate, an Activator of PKC. Second World Congress on Biologically Active Atrial Peptides 248-250, 1988.

Nambi, P., Aiyar, N., Stassen, F., Crooke, S.T. Inter-Receptor Regulation in Vascular Smooth Muscle Cells. Vasopressin in Cellular and Integrative Function, Cowley, A., Laird, S., and Ausiello, B., (eds.) Raven Press, 1988, 47-54.

Winkler, J.D., Sarau, H.M., Foley, J.J., Crooke, S.T. Phorbol 12-Myristate 13-AcetateInhibition of Leukotriene D4-induced Signal Transduction was Rapidly Reversed by Staurosporine. Biophy Res Commun 157:521-529, 1988.

Butt, T.R. et al. Mechanisms of Mutant Ubiquitin Action and Dynamics of Ubiquitin Cycle in Cells. The Ubiquitin System, Current Communication, Cold Spring, NY, 1988.

Mong, S., Wu, H.L., Wong, A., Sarau, H.M., Crooke, S.T. Leukotriene D4 Receptor Mediated Phosphoinositol Hydrolysis and Calcium Mobilization in Rat Basophilic Leukemia Cells. J Pharmocol Exp Ther 247:803-813, 1988.

Aiyar, N. et al. Solubilization of a Guanine Nucleotide Sensitive Form of Vasopressin V2 Receptors from Porcine Kidney. Archives Biochem Biophys 268:698-706, 1989.

Ecker, D.J. et al. Effects of Altered Ubiquitin Structures on the Ubiquitin Pathway. Current Communications in Mol Biol, Cold Spring Harbor, NY, 1988.

Ecker, D.J. et al. Ubiquitin Function Studied by Disulfide Engineering. Biol Chem 264:1887-1893, 1989.

Tan, K.B., Per, S.R., Boyce, R.A., Mirabelli, C.K., Crooke, S.T. Altered Expression and Transcription of Topoisomerase II Gene in Nitrogen Mustard-Resistant Human Cells. Biochem Pharmacol 37:4413-4416, 1988.

Butt, T.R., Khan, M.I., Marsh, J., Ecker, D.J., Crooke, S.T. Ubiquitin-Metallothionein Fusion Protein Expression in Yeast. J Biol Chem 263:16364-16371, 1988.

Mong, S., Chi-Rosso, G., Hay, D.W., Crooke, S.T. Subcellular Localization of Leukotriene D4 Receptors in Sheep Tracheal Smooth Muscle. Mol Pharmacol 34:590-596, 1988.

Winkler, J.D., Sarau, H.M., Foley, J.J., Crooke, S.T. Leukotriene D4 Induced Homologous Desensitization in Basal and Differentiated U-937 Cells: Characterization with the Partial Agonist Leukotriene Eg1 and Assessment of Receptor Reserve. J Pharmacol Exp Ther 247:54-62, 1988.

Nambi, P., Whitman, M., Aiyar, N., Crooke, S.T. Inhibition of Formation of Cyclic AMP and Cyclic GMP by Vasopressin in Smooth-Muscle Cells is Insensitive to Pertussis Toxin. Biochem J 254:449-453, 1988.

Mirabelli, C.K., Sung, C.M., McCabe, L.F.F., Crooke, S.T., Johnson, R.K. A Murine Model to Evaluate the Ability of in vitro Clonogenic Assays to Predict the Response of Tumors in vivo. Cancer Research 48:5447-5454, 1988.

Balcarek, J.M., Theisen, T., Varrichio, A., Crooke, S.T. Isolation and Characterization of a cDNA Clone Encoding Rat 5-Lipoxygenase. J Biol Chem 263:13937-13941, 1988.

Crooke, S.T. Knowledge and Power. Vital Speeches of the Day 23:732-735, 1988.

Wong, A., Hwang, S.M., Cook, M., Hogaboom, C.K., Crooke, S.T. Interactions of 5Lipoxygenase with Membranes: Studies on the Association of Soluble Enzyme with Membranes and Alterations in Enzyme Activity. Biochemistry 27:6763-6769, 1988.

Bennett, C.F., Balcarek, J., Varrichio, A., Crooke, S.T. Molecular Cloning and Complete Amino Acid Sequence of Form I Phosphoinositide- Specific Phospholipase C. Nature 334:268-270, 1988.

Winkler, J.D., Sarau, H.M., Foley, J.J., Mong, S., Crooke, S.T. Leukotriene B4-induced Homologous Desensitization of Calcium Mobilization and Phosphoinositide Metabolism in U-937. J Pharmacol Exp Ther 246:204-210, 1988.

Stadel, J.M., Rebar, R., Crooke, S.T. Alkaline Phosphatase Relieves Desensitization of Adenylyl Cyclase-Coupled Beta-Adrenergic Receptors in Avian Erythrocyte Membranes. Biochem J 252:771-776, 1988.

Crooke, S.T., Nambi, P., Aiyar, N., Stassen, F., Grillone, L. Vasopressin V1– Receptors and Interreceptor Regulation in Vascular Smooth Muscle Cell. Biochem Pharmacol 37:2105-2108, 1988.

Crooke, S.T., Mong, S., Sarau, H.M., Winkler, J.D. and Vegesna, V.K. Mechanisms of Regulation of Receptors and Signal Transduction Pathways for the Peptidyl Leukotrienes. Ann NY Acad Sci 524:153-161, 1988.

Vegesna, R.V., Wu, H.L., Mong, S., Crooke, S.T. Staurosporine Inhibits Protein Kinase C and Prevents Phorbol Ester Mediated Leukotriene D, Receptor Desensitization in RBL-1 Cells. Mol Pharmacol 33:537-542, 1988.

Crooke, S.T. et al. Eicosanoid Receptors. In Receptor Pharmacology and Function, O’Brien, (ed) Marcel Decker, Inc, 599-621, 1988.

Mong, S., Chi-Rosso, G., Clark, M.A., Crooke, S.T. Subcellular Localization of Leukotriene D4 Receptors in Sheep Tracheal Smooth Muscle. Mol Pharmacol 34:590-596, 1988.

Mong, S., Miller, J., Wu, H.L., Crooke, S.T. Leukotriene D4 Receptor-Mediated Hydrolysis of Phosphatidylinositol and Mobilization of Calcium in Sheep Tracheal Smooth Muscle Cells. J Pharm Exp Ther 244:508-515, 1988.

Clark, M.A., Chen, M.J., Crooke, S.T., Bomalaski, J.S. Tumor Necrosis Factor (Cachectin) Induces Phospholipase A2 Activity and the Synthesis of a Phospholipase A2 Activating Protein (PLAP) in Endothelial Cells. Biochem J 250:125-132, 1988.

Vegesna, R.V.K., Mong, S., Crooke, S.T. Leukotriene D4-lnduced Activation of Protein Kinase C in Rat Basophilic Leukemia Cells. Eur J Pharmacol 147:387-396, 1988.

Crooke, S.T. et al. LTD4 Receptors and Signal Transduction Processes. In Cellular and Molecular Aspects of Inflammation, Plenum Press, 1988, Chapter 16, 321-334.

Jonnalagadda, J., Ecker, D.J., Sternberg, E.J., Butt, T.R., Crooke, S.T. Ubiquitin Carboxy Terminal Peptides: Substrates for Ubiquitin Activating Enzyme. J Biol Chem 263:5016-5019, 1988.

Stadel, J.M., Crooke, S.T. Differential Effects of Fluoride on Adenylyl Cyclase Activity and Guanine Nucleotide Regulation of Agonist High-Affinity Receptor Binding. Biochem J 254:15-20, 1988.

Winkler, J.D., Mong, S., Crooke, S.T. Leukotriene D4 Induced Homologous Desensitization of Calcium Mobilization in Rat Basophilic Leukemia Cells. J Pharmacol Exp Ther 244:449-455, 1988.

Grillone, L., Stassen, F., Clark, M.A., Godfrey, R.W., Crooke, S.T. Vasopressin Induces V1 Receptors to Activate P1- and PC Specific Phospholipase C and Stimulates the Release of Arachidonic Acid by at Least Two Pathways in the Smooth Muscle Cell Line, A-10. J Biol Chem 263:2658-2663, 1988.

Stadel, J.M., Johnson, R.K., Mirabelli, C.K., Powers, D.A., Sung, C.M., Faucette, L.F., McCabe, F.L., Crooke, S.T. Tumorigenicity of the CYC-Variant of S49 Murine Lymphoma Deficient in the Gsalpha Subunit of Adenylate Cyclase. Cancer Res 48:641-644, 1988.

Mirabelli, C.K., Snyder, R.M., Crooke, S.T. Recent advances in understanding the molecular pharmacology of gold. Gold. Proceedings of the First International Conference on Gold and Silver in Medicine 1:81-96, 1987.

Ecker, D.J. et al. Ubiquitin, Nature’s Most Conserved Protein as a Model for Protein Engineering. Molecular and Cellular Biology, New Series, Vol 69, Protein Structure Folding and Design 2, (ed) D. Oxender, Alan R. Liss, Inc, New York, NY, 1987, 119-129.

Stadel, J.M., Nakada, M.T., Crooke, S.T: Molecular Mechanisms of Beta-Adrenergic Receptor Regulation. Proceedings of the 10th International Congress of Pharmacology. Exerpta Medical, 7-20, 1987.

Mirabelli, C.K., Hill, D.T., Faucette, L.F., McCabe, F.L., Girard, G.R., Bryan, D.B., Sutton, B.M., Leary Barus, J.O., Crooke, S.T., Johnson, R.K. Antitumor Activity of Bis(diphenylphosphino) alkanes, Their Gold(l) Coordination Complexes and Related Compounds. J Med Chem 30:2181-2190, 1987.

Jonnalagadda, S., Butt, T.R., Marsh, J., Sternberg, E.J., Mirabelli, C.K., Ecker, D.J., Crooke, S.T. Expression and Accurate Processing of Yeast Penta-Ubiquitin in E. coli. J Biol Chem 262:17750-17756, 1987.

Clark, M.A., Conway, T.M., Crooke, S.T. HPLC Analysis of [3H]-Arachidonic Acid Metabolities Produced by Smooth Muscle and Endothelial Cells in Response to Leukotriene D4. J Liq Chromatogr 10:2707-2719, 1987.

Stadel, J.M., Poksay, K.S., Nakada, M.T., Crooke, S.T. Regulation of Beta-adrenoceptor Number and Subtype in 3T3-L1 Preadipocytes by Sodium Butyrate. Eur J Pharmacol 143:35-44, 1987.

Drake, F.H., Zimmerman, J.P., McCabe, F.L., Bartus, H.F., Per, S.R., Sullivan, D.M., Ross, W.E., Mattern, M.R., Johnson, R.K., Crooke, S.T., et al. Purification of Topoisomerase II from Amsacrine-resistant P388 Leukemia Cells. J Biol Chem 262:16739-16747, 1987.

Strohsacker, M.W., Minnich, M.D., Clark, M.A., Shorr, R.G., Crooke, S.T. Selective Purification of Cardiac Myosin by a High-Performance Salicylate Affinity Column. J Chromatog 435:185-192, 1987.

Bennett, C.F., Mong S., Wu, H.L., Clark, M.A., Wheeler, L., Crooke, S.T. Inhibition of Phosphoinositide-Specific Phospholipase C by Manoalide. Mol Pharmacol 32:587-593, 1987.

Rush, G.F., Smith, P.F., Alberts, D.W., Mirabelli, C.K., Snyder, R.M., Crooke, S.T., Sowinski J., Jones, H.B., Bugelski, P.J. The Mechanism of Acute Cytotoxicity of Gold (I) Complexes: Triethylphosphine Gold Chloride-lnduced Lipid Peroxidation and Morphological Changes in Isolated Hepatocytes. Toxicol Appl Pharmacol 90:377-390, 1987.

Ecker, D.J. et al. Gene Synthesis, Expression, Structures and Functional Activities of Site Specific Mutants of Ubiquitin. J Biol Chem 262:14213-14221, 1987.

Bennett, C.F., Crooke, S.T. Purification and Characterization of a Phosphoinositide-Specific Phospholipase C from Guinea Pig Uterus. J Biol Chem 262:13789-13797, 1987.

Snyder, R., Mirabelli, C.K., Clark, M., Ziegler, J., Crooke, S.T. Effect of Auranofin and other Gold Complexes on the Activities of Phosolipase C. Mol Pharmacol 32:437-442, 1987.

Stadel, J.M., Rebar, R., Crooke, S.T. Catecholamine-lnduced Desensitization of Adenylate Cyclase Coupled Beta-Adrenergic Receptors in Turkey Erythrocytes: Evidence for a Two- Step Mechanism. Biochemistry 26:5861-5866, 1987.

Aiyar, N., Nambi, P., Stassen, F.L., Crooke, S.T. Effects of N-Ethylmaleimide on Arginine Vasopressin-lnduced Responses in an Established Smooth Muscle Cell Line. J Pharmacol Exp Ther 242:217-221, 1987.

Mong, S., Wu, H.L., Miller, J., Hall, P.F., Gleason, J.G., Crooke, S.T. SKF 104353, A High Affinity Antagonist For Human and Guinea Pig Lung Leukotriene D4 Receptor Blocked Phosphatidylinsitol Metabolism and Thromboxane Synthesis Induced by LTD4. Mol Pharmacol 32:223-229, 1987.

Shorr, R.G.L., Minnich, M.D., Varrichio, A., Strohsacker, M.W., Gotlib L., Kruse, L.I., DeWolf, W.E. Jr, Crooke, S.T. Immuno Cross-Reactivity Suggest That Catecholamine Biosynthesis Enzymes and Beta Adrenergic Receptors May Be Related. Mol Pharmacol 32:195-200, 1987.

Varrichio, A., Shorr, R.G.L, Strohsacker, M.W., Minnich, M., Crooke, S.T. Rapid Generation of Peptides for N-Terminal Sequence Analysis. In Proceedings of the 6th International Conference on Methods in Protein Sequence Analysis, Humana Press, Inc. 345- 350, 1987.

Khan, M.I., Ecker, D.J., Butt, T., Gorman, J.A., Crooke, S.T. A Vector for the Construction of Gene Libraries and the Expression of Heterologous Genes in Saccharamyces Cerevisiae. Plasmid 17:171-172, 1987.

Snyder, R.M., Mirabelli, C.K., Crooke, S.T. The Cellular Pharmacology of Auranofin. Semin Arthritis Rheum 17:71-80, 1987.

Per, S., Mattern, M.R., Mirabelli, C.K., Drake, F.H., Johnson, R.K., Crooke, S.T. Characterization of a Subline of P388 Leukemia Resistant to Amsacrine: Evidence of Altered Topoisomerase II Function. Mol Pharmacol 32:17-25, 1987.

Aiyar, N., Nambi, P., Stassen, F., Crooke, S.T. Solubilization and Reconstitution of Vasopressin V1 Receptors of Rat Liver. Mol Pharmacol 32:34-36, 1987.

Coffer, M., Shaw, C.F., Hormann, A.L., Mirabelli, C., Crooke, S.T. Thiol Competition for Et3 PAuS-Albumin: A Nonenzymatic Mechanism for Et3PO Formation. J Inorg Biochem 130:177-187, 1987.

Crooke, S.T., Mong, S., Clark, M., Hogaboom, G.K., Lewis, M., Gleason, J.L. Leukotriene Receptors and Signal Transduction Mechanism. In Biochemical Actions of Hormones, (ed) Dr. Gerald Litwack, Academic Press, 1987, 81-139.

Gleason, J.G. et al. High-Affinity Leukotriene Receptor Antagonists. Synthesis and Pharmacological Characterization of 2-Hydroxy- 3[(2carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyq propanoic Acid. J Med Chem 30:959-961, 1987.

Nambi, P., Whitman, M., Aiyar, N., Stassen, F., Crooke, S.T. An Activator of Protein Kinase C (phorbol dibutyrate) Attenuates ANF-Stimulated cGMP Accumulation in Smooth Muscle Cells. BioChem J 244:481-484, 1987.

Ecker, D.J., Khan, M.I., Marsh, J., Butt, T., Crooke, S.T. Chemical Synthesis and Expression of a Cassette Adapted Ubiquitin Gene. J Biol Chem 262:3524-3527, 1987.

Monia, B.P. et al. Induction of Metallothionein is Correlated with Resistance to Auranofin, a Gold Compound, in Chinese Hamster Ovary Cells. Mol Pharmacol 31:21-26, 1987.

Bennett, C.F., Mong, S., Clark, M.A., Kruse, L.I., Crooke, S.T. Differential Effects of Manoalide on Secreted and Intracellular Phospholipases. Biochem Pharmacol 36:733-740, 1987.

Nakada, M.T., Stadel, J.M., Poksay, K.S., Crooke, S.T. Glucocorticoid Regulation of β Adrenergic Receptors in 3T3-L1 Preadipocytes. Mol Pharmacol 31:377-384, 1987.

Wong, A., Hwang, S.M., Cheng, H.Y., Crooke, S.T. Structure-Activity Relationships of β-Adrenergic Receptor-Coupled Adenylate Cyclase: Implications of a Redox Mechanism for the Action of Agonist at β-Adrenergic Receptors. Mol Pharmacol 31:368-376, 1987.

Aiyar, N., Nambi, P., Whitman, M., Stassen, F., Crooke, S.T. Phorbal Ester-Mediated Inhibition of Vasopressin and β-Adrenergic Responses in a Vascular Smooth Muscle Cell Line. Mol Pharmacol 31:180-184, 1987.

Snyder, R.M., Mirabelli, C.K., Crooke, S.T. Cellular Interactions of Auranofin and a Related Gold Complex with RAW 264.7 Macrophages. Biochem Pharmacol 36:647-654, 1987.

Clark, M., Conway, T., Shorr, R., Crooke, S.T. Identification and Isolation of a Mammalian Protein which is Antigenically and Functionally Related to the Phospholipase A2 Stimulatory Peptide Melittin. Biol Chem 262:4402-4406, 1987.

Stassen, F. et al. Identification and Characterization of Vascular (V1) Vasopressin Receptors of an Established Smooth Muscle Cell Line. Mol Pharmacol 31:259-266, 1987.

Stassen, F. et al. A Novel Radiolabelled Vasopressin Antagonist: l3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926. Mol Pharmacol 31:267-272, 1987.

Sarau, H., Mong, S., Foley, J., Wu, H., Crooke, S.T. Identification and Characterization of Leukotriene D4 Receptors and Signal Transduction Processes in Rat Basophilic Leukemia Cells. J Biol Chem 262:4034-4041, 1987.

Mattern, M., Mong, S., Bartus, H., Mirabelli, C., and Crooke, S.T. Relationship between the Intracellular Effects of Camptothecin and the Inhibition of DNA Topoisomerase I in Cultured L1210 Cells. Cancer Res 47:1793-1798, 1987.

Crooke, S.T. and Snyder, R.M. The Cellular and Molecular Pharmacology of Auranofin and Related Gold Complexes. Scand J Rheumatol Suppl 63:1-18, 1987.

Perchonock, C.D. et al. Synthesis and Structure-Activity Relationship Studies of a Series of 5-Aryl-4,6-dithianonanedioc Acids and Related Compounds: A Novel Class of Leukotriene Antagonists. J Med Chem 29:1442- 1452, 1986.

Hogaboom, G.K. et al. Purification, Characterization, and Structural Properties of a Single Protein from Rat Basophilic Leukemia (RBL-1) Cells Processing 5-Lipoxygenase and Leukotriene A2 Synthetase Activities. Mol Pharmacol 30:510-519, 1986.

Ecker, D.J., Hempel, J.C., Sutton, B.M., Kirsch, R. and Crooke, S.T. Reactions of the Metallodrug Auranofin [(1-Thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S)(triethylphosphine)gold] with Biological Ligands Studied by Radioisotope Methodology. J Inorg Chem 25:3139-3143, 1986.

Clark, M., Bomalaski, J.S., Conway, T., Wartell, J., and Crooke S.T. Differential Effects of Aspirin and Dexamethasone on Phospholipase A2 and C Activities and Arachidonic Acid Release from Endothelial Cells in Response to Bradykinin and Leukotriene D. Prostaglandins 32:703-708, 1986.

Mong, S. et al. Leukotriene B4 Induces Formation of Inositolphosphates in Rat Peritoneal Polymorphonuclear Leukocytes. Mol Pharmacol 30:235-242, 1986.

Nambi, P., Whitman, M., Aiyar, N. and Crooke, S.T. Vasopressin -Mediated Inhibition of Atrial Natriuretic Factor-Stimulated cGMP Accumulation in an Established Smooth Muscle Cell Line. Proc Natl Acad Sci USA 83:8492-8495, 1986.

Mong, S., Hoffman, K., Wu, H.L. and Crooke, S. Leukotriene Induced Hydrolysis of Inositol Lipids in Guinea Pig Lung: Mechanism of Signal Transduction. Mol Pharmacol 31:35-41, 1986.

Berners-Price, S. et al. The In vivo Antitumor Activity and In vitro Cytotoxic Properties of Bis[1,2-bis(diphenylphosphino)ethane]gold(l) Chloride. Cancer Research 46:5486-5493, 1986.

Stadel, J.M., Rebar, R., Shorr, R.G.L., Nambi, P. and Crooke, S.T. Biochemical Characterization of Phosphorylated Beta-Adrenergic Receptors from Catecholamine Desensitized Turkey Erythrocytes. Biochemistry 25:3719-3724, 1986.

Snyder, R.M. et al. Modulation of the Antitumor and Biochemical Properties of Bis (diphenylphosphino) ethane with metals. Cancer Res 46:5054-5060, 1986.

Monia, B.P., Butt, T.R., Ecker, D.J., Mirabelli, C.K. and Crooke, S.T. Metallothionein Turnover in Mammalian Cells: Implications in Metal Toxicity. Biol Chem 261:10957- 10959, 1986.

Mong S., Hogaboom, G.K., Clark, M.A. and Crooke, S.T. Molecular Heterogeneity of Leukotriene Receptors. In Receptor Binding in Drug Research, (ed) O’Brien, A. Marcel Dekker, Inc, Chapter 10, 204-230, 1986.

Mong, S., Wu, H.L., Clark, M.A., Gleason, J.G. and Crooke, S.T. Leukotriene D4 Receptor Mediated Synthesis and Release of Arachidonic Acid Metobolites in Guinea Pig Lung; Induction of Thromboxane and Prostacyclin Biosynthesis by Leukotriene D4. J Pharmacol Exp Ther 239:63, 1986.

Ecker, DJ. et al. Yeast Metallothionein Function in Metal lon Detoxification. J Biol Chem 261:16895-16900, 1986.

Clark, M., Conway, T.M., Bennett, C.F., Crooke, S.T and Stadel, J.M. Islet Activating Protein Inhibits Leukotriene D4 and Leukotriene C4 but not Bradykinin- or Calcium lonophore- induced Prostacyclin Synthesis in Bovine Endothelial Cells. Proc Natl Acad Sci USA 83 :7320-7324, 1986.

Nambi, P., Whitman, M., Stassen, F.L. and Crooke, S.T. Vascular Vasopressin Receptors Mediate Inhibition of Beta-Adrenergic Receptor-lnduced Cyclic AMP Accumulation. J Pharmacol Exp Ther 237:143-146, 1986.

Wong, A., Huang, C.H., Hwang, S.M., Prestayko, A. and Crooke, S.T. Formation of the Thiol Adducts of 4′ -(9-Acridinylamino) Methanesulon -m-Anisidide and their Binding to Deoxyribonucleic Acid. Biochem Pharmacol 35:1655-1662, 1986.

Crooke, S.T. Editorial, Anti-Cancer Drug Design 1:59-63, 1986.

Mirabelli, C.K., Zimmerman, J.P., Bartus, H.R., Sung, C.M. and Crooke, S.T. Inter-strand Cross Links and Single-Strand Breaks Produced by Gold (I) and (111) Coordination Complexes. Biochem Pharmacol 35:1435-1443, 1986.

Mong, S., Wu, H.L., Stadel, J.M., Clark, M.A. and Crooke, S.T. Solubilization of [3H]Leukotriene D4 Receptor Complex from Guinea Pig Lung Membranes. Mol Pharmacol 29:235-243, 1986.

Clark, M.A., Littlejohn, D., Mong, S. and Crooke, S.T. Effect of Leukotrienes, Bradykinin and Calcium lonophore (A 23187) on Bovine Endothelial Cells: Release of Prostacyclin. Prostaglandins 31:157-166, 1986.

Butt, T.R., Sternberg, E.J., Mirabelli, C.K. and Crooke, S.T. Regulation of Metallothionein Gene Expression in Mammalian Cells by Gold Compounds. Mol Pharmacol 29:204-210, 1986.

Mirabelli, C.K. et al. Interactions of Gold Coordination Complexes with DNA. Biochem Pharmocol 35:1427-1433, 1986.

Wong, A., Cheng, H.Y. and Crooke, S.T. Identification of the Active Species in Deoxyribonucleic Acid Breakage Induced by4′-(9-Acridinylamino) MethanesuHon-m-Anisidide and Copper. Biochem Pharmacol 35:1071-1078, 1986.

Snyder, R.M., Mirabelli, C.K. and Crooke, S.T. Cellular Association, Intracellular Distribution and Efflux of Auranofin via Sequential Ligand Exchange Reactions. Biochem Pharmacol 35:923-932, 1986.

Huang, C.H. and Crooke, S.T. Effects of Structural Modifications of Anti-tumor Antibiotics Luzopeptins on Cell Growth and Macromolecule Biosynthesis. Anti-Cancer Drug Design 1:87-94, 1986.

Mirabelli, C.K. et al. Correlation of the In vitro Cytotoxic and In vivo Antitumor Activities of Gold(l) Coordination Complexes. J Med Chem 29:218-223, 1986.

Mirabelli, C. et al. Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: a novel antitumor agent. Anti-Cancer Drug Design 1:223- 234, 1986.

Flaim, K.E., Gessner, G.W., Crooke, S.T., Heys, J.R. and Weinstock, J. Regulation of Agonist and Antagonist Binding to Striatal D-1 Dopamine Receptors: Studies using the Selective D-1 Antagonist [3H] SK&F R-83566. Life Sci 38:2087-2096, 1986.

Crooke, S.T. et al. Cellular and Molecular Pharmacology of Auranofin and Related Gold Complexes. Biochem Pharmacol 35:3423-3431, 1986.

Clark, M.A. et al. Leukotriene D4 Treatment of Bovine Aortic Endothelial Cells and Murine Smooth Muscle Cells in Culture Results in an Increase in Phospholipase A2 Activity. J Biol Chem 261:10713-10718, 1986.

Shorr, R.G.L. et al. Evidence for Tyrosine at the Ligand Binding Center of Beta-Adrenergic Receptors. Biochem Pharmacol 35:3821-3825, 1986.

Nambi, P. et al. Induction of Functional β-Adrenergic Receptors in Rat Aortic Smooth Muscle Cells by Sodium Butyrate. Biochem Pharmacol 35:3813-3820, 1986.

Aiyar, N., Nambi, P., Whitman, M., Stassen, F.L. and Crooke, S.T. Vascular Vasopressin Receptors Mediate Phosphatidylinositol Turnover and Calcium Efflux in an Established Smooth Muscle Cell Line. Life Sci 39:37-45, 1986.

Lewis, M.A., Mong, S., Vessella, R.L. and Crooke, S.T. Identification and Characterization of Leukotriene D4 Receptors in Adult and Fetal Human Lung. Biochem Pharmacol 34:4311-4318, 1985.

Shorr, R.G.L. et al. Membrane Bound Hormone Receptor Purification and Characterization by HPLC. In Progress in HPLC Vol 1:9-26, Parvez et al (eds.) VNU Science Press, 1985.

Crooke, S.T. Biotechnology. Rutgers Computer and Technology Law Journal 11:101-116, 1985.

Crooke, S.T. The Opportunities and Challenges of Drug Discovery and Development as we Approach the Twentieth Century. Leaders 8:(3), 1985.

Hogaboom, G.K., Mong, S., Stadel, J.M. and Crooke, S.T. Characterization of [3H] Leukotriene D4 Binding Sites in Guinea-Pig Ventricular Myocardium. J Pharmacol Exp Ther 233:686-693, 1985.

Huang, C.H. and Crooke, S.T. Effects of Structural Modifications of Antitumor Antibiotics (Luzopeptins) on the Interactions with Deoxyribonucleic Acid. Cancer Res 45:3768-3773, 1985.

Perchonock, C.D. et al. Synthesis and Pharmacological Characterization of 5-(2-Dodecylphenyl)-4,6-dithianonanedioic Acid and 5-[2-(8-Phenyloctyl)phenyl]-4,6-dithianonanedioic Acid: Prototypes of a Novel Class of Leukotriene Antagonists. J Med Chem 28:1145-1147, 1985.

Shorr, R.G.L. et al. Molecular Structure of the b-Adrenergic Receptor. Biochemistry 24:6869-6875, 1985.

Mirabelli, C.K. et al. Application of a Tissue Culture Microtiter Test for the Detection of Cytotoxic Agents from Natural Products. J Antibiot (Tokyo) 38:758-766, 1985.

Allaudeen, H.S., Snyder, R.A. and Crooke, S.T. Effects of Coordinated Gold Compounds on In vitro and In Situ DNA Replication. Biochem Pharmacol 34:3243-3250, 1985.

Mong, S. et al. Molecular Heterogeneity of Leukotriene Receptors: Correlation of Smooth Muscle Contraction and Radioligand Binding in Guinea Pig Lung. J Pharmacol Exp Ther 234:316-325, 1985.

Mong, S. et al. Leukotriene E4 Binds Specifically to LTD4 Receptors in Guinea Pig Lung Membranes. Eur J Pharmacol 109:183-192, 1985.

Flaim, K.E., Gessner, W., Crooke, S.T., Sarau, H.M. and Weinstock, J. Binding of a Novel Dopaminergic Agonist Radioligand [3H]-Fenoldopam (SKF 82526) to D-1 Receptors in Rat Striatum. Life Sci 36:1427-1436, 1985.

Wong, A. and Crooke, S.T. Studies on the Fluorescence Labeling of Human Red Blood Cell Membrane Ghosts with 4‘(9-Acridinylamino) methanesulfon-m-anisidide. Pharmacol 34:3265-3273, 1985.

Mirabelli, C.K., Huang, C.H., Fenwick, R.G. and Crooke, S.T. Quantitative Measurement of Single- and Double-Strand Breakage of DNA in Escherichia Coil by the Antitumor Antibiotics Bleomycin and Talisomycin. Antimicrob Agents Chemother 27:460-467, 1985.

Clark, M.A., Cook, M., Mong, S. and Crooke, S.T. The Binding of Leukotriene C4 and Leukotriene D4 to Membranes of Smooth Muscle Cell Lines (BC3H1) and Evidence that Leukotriene Induced Contraction in these Cells is Mediated by Thromboxane, Protein and RNA Syntheses. J Pharmacol 116:207-220, 1985.

Hogaboom, G.K., Mong, S., Stadel, J.M. and Crooke, S.T. Characterization of Guinea Pig Myocardial Leukotriene C4 Binding Sites: Regulation by Cations and Sulfhydryl- Directed Reagents. Mol Pharmacol 27:236-245, 1985.

Mirabelli, C.K. et al. Evaluation of the In vivo Antitumor Activities and In vitro Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Model. Cancer Res 45:32-39, 1985.

Crooke, S.T. An Overview of Research and Development at Smith Kline & French. J Postgrad Med NS1:103-108, 1985.

Mong, S. et al. Regulation of Ligand Binding to Leukotriene D4 Receptors: Effects of Cations and Guanine Nucleotides. Eur J Pharmacol 106:241-253, 1984.

Mong, S. et al. Identification of Leukotriene D4 Specific Binding Sites in the Membrane Preparation Isolated from Guinea Pig Lung. Prostaglandins 28:805-822, 1984.

Wong, A., Huang, C.H. and Crooke, S.T. Mechanism of Deoxyribonucleic Acid Breakage Induced by 4′(9-Acridinylamino) methanesulfon-m-anisidide and Copper: Role for Cuprous lon and Oxygen Free Radicals. Biochemistry 23:2946-2952, 1984.

Wong, A., Huang, C.H. and Crooke, S.T. Deoxyribonucleic Acid Breaks Produced by 4′(9- Acridinylamino) methanesulphon-m-anisiside and Copper. Biochemistry 23:2939-2945, 1984.

Lewis, M.A. et al. Identification of Specific Binding Sites for Leukotriene C, in Human Fetal Lung. Prostaglandins 27:961-974, 1984.

Butt, T.R. et al. Copper metallothionein of yeast, structure of the gene and regulation of expression (Saccharomyces cerevisiae; metal induced gene; metallothionein promoter – galactokinase gene fusions). Proc Natl Acad Sci USA 81:3332-3336, 1984.

Butt, T.R., Sternberg, E., Herd, J. and Crooke, S.T. Cloning and Expression of a Yeast Copper Metallothionein Gene. Gene 27:23-33, 1984.

Clark, M.A. et al. Leukotriene C4 ([3H]-LTC4) Binding to Membranes Isolated from a Hamster Smooth Muscle Cell Line (DDT1 MF2). Life Sci 35:441-448, 1984.

Mong, S., Wu, H.L., Hogaboom, G., Clark, M.A. and Crooke, S.T. Characterization of the leukotriene D4 receptor in guinea-pig lung. Eur J Pharmacol 102:1-11, 1984.

Bartus, H.R. et al. An Improved Genetically Modified Strain of E. Coil for Prescreening of Antineoplastic Agents. Antimicrob Agents Chemother 25:622- 625, 1984.

DuVernay, V.H. and Crooke, S.T. DNA Binding Studies on Several New Anthracycline Antitumor Antibiotics. llL The Stereospecific Orientation of the Carbomethoxy-Group at Position 10 of the Class II Anthracycline. Proceedings of the First International Telesymposium on Medicinal Chemistry, February 29, 1984, M Kuchar, (ed) JR Prous Science, Barcelona, Spain, 265-278.

Hogaboom, G.K., Mong, S., Wu, H.L. and Crooke, S.T. Peptidoleukotrienes: Distinct Receptors for Leukotriene C4 and D4 in the guinea pig lung. Biophys Res Commun 116:1136-1143, 1983.

Crooke, S.T., Mirabelli, C.K., Huang, C.H., Mong, S. and Wong, A. Sequence and Topology: Specific Attack on DNA and Chromatin. In Progress in Cancer Research and Therapy Development of Target-Oriented Anticancer Drugs, Cheng, Y.C., Goz, B. and Minkoff, M. (eds), Raven Press, New York, NY, 1983, 207-218.

Crooke, S.T. Antitumor Antibiotics 11: Actinomycin D, Bleomycin, Mitomycin C and Other Antibiotics. In The Cancer Pharmacology Annual, Chabner, B.A. and Pinedo, H.M. (eds), Excerpta Medica, Amsterdam, 1983, 69-79.

Huang, C.H., Mirabelli, C.K., Mong, S. and Crooke, S.T. The Effects of DNA Superhelical Changes Induced by Ethidium Bromide on the DNA-degrading Activity of Two Antitumor Antibiotics, Bleomycin and Phleomycin. Cancer Res 43:2849-2856, 1983.

Huang, C.H., Mirabelli, C.K., Mong, S. and Crooke, S.T. Intermolecular Cross-Linking of DNA through Bifunctional Intercalation of an Antitumor Antibiotic, Luzopeptin A (BBM-928A). Cancer Res 43:2718-2724, 1983.

Mirabelli, C.K. and Crooke, S.T. Pharmacology of Auranofin – A Review and Future Perspective. In Current Clinical Practice, Series 7, Excerpta Medica, Amsterdam, 1983, 17-31.

Crooke, S.T and Mirabelli, C.K. Molecular Mechanisms of Action of Auranofin and Other Gold Complexes as Related to Their Biologic Activities. Am J Med 75:109-113, 1983.

Mirabelli, C.K, Huang, C.H. and Crooke, S. Role of DNA Topology in Altering Site/Sequence Specificity of Cleavage of DNA by Bleomycin and Talisomycin. Biochemistry 22:300-306, 1983.

Ginsberg, S.J. et al. Cyclophosphamide, Doxorubicin, Vincristine, and Low- Dose Continuous Infusion Bleomycin in Non-Hodgkins Lymphoma. Cancer 49:1346-1352, 1982.

Nazimiec, M., Crooke, S.T. and Prestayko, A.W. Effects of Cis-Diamminedichloroplatinum (CDDP) on HeLa Cell Non-Histone Nuclear Proteins. Cancer Chemother Pharmacol 9:36-40, 1982.

Comis, R.L. et al. A Phase I and Clinical Pharmacology Study of Intravenously Administered Carminomycin in Cancer Patients in the United States. Cancer Res 42:2944-2948, 1982.

Crooke, S.T. Antitumor Antibiotics 11: Actinomycin D, Bleomycin, Mitomycin C and Other. In Cancer Chemotherapy, 1982 Pinedo, HM (ed), 1982, 69-79.

Prestayko, A.W., DuVernay, V.H., Long, B.H. and Crooke, S.T. Effects of Anthracyclines on Macromolecules and Their Syntheses. In Anthracycline Antibiotics in Cancer Therapy, Muggia, F., Yang, C.W., Carter, S.K. (eds), Martinus Nijhoff, 1982, 117-124.

Mirabelli, C.K., Ting, A., Huang, C.H., Mong, S. and Crooke, S.T. Bleomycin and Talisomycin Sequence-specific Strand Scission of DNA: A Mechanism of Double-Strand Cleavage. Cancer Res 42:2779-2785, 1982.

Seeber, S., Osieka, R., Schmidt, C.G., Achterrath, W. and Crooke, S.T. In vivo Resistance towards Anthracyclines, Etoposide and cis-Diamminedichloroplatinum(11). Cancer Res 42:4719-4725, 1982.

Crooke, S.T. A Comparison of the Molecular Pharmacology of Gold and Platinum Complexes. J Rheumatol Suppl 9:61-70, 1982.

Mirabelli, C.K., Beattie, W.G., Huang, C.H., Prestayko, A.W. and Crooke, S.T. Comparison of the Sequences at Specific Sites on DNA Cleaved by the Antitumor Antibiotics Talisomycin and Bleomycin. Cancer Res 42:1399-1404, 1982.

Huang, C.H., Prestayko, A.W. and Crooke, S.T. Bifunctional Intercalation of Antitumor Antibiotics BBM-928A and Echinomycin with DNA. Effects of Intercalation on DNA-Degradative Activity of Bleomycin and Phleomycin. Biochemistry 21:3704-3710, 1982.

Long, B.H., Willis, C.E., Prestayko, A.W. and Crooke, S.T. Effect of Anthracycline Analogues on the Appearance of Newly Synthesized Total RNA and Messenger RNA in the Cytoplasm of Erythroleukemia Cells. Mol Pharmacol 22:152-157, 1982.

Issell, B.F. et al. Dibromodulcitol plus Bleomycin Compared with Bleomycin Alone in Head and Neck Cancer. Cancer Chemother Pharmacol 8:171-173, 1982.

Mong, S., Eubanks, D.C., Prestayko, A.W. and Crooke, S.T. Characterization of in vitro DNA Breakage and Cross-Linking Induced by is(isopropylamine)-trans-dihydroxy- cisdichloroplatinum(lV). Biochemistry 21:3174-3180, 1982.

Mirabelli, C.K., Huang, C.H., Prestayko, A.W. and Crooke, S.T. Structure-Activity Relationships Involved in the Site-Specific Fragmentation of Linear Duplex DNAs by Talisomycin and Bleomycin Analogs. Cancer Chemother Pharmacol 8:57-65, 1982.

DuVernay, V.H., Eubanks, D., Perales, R., Prestayko, A.W. and Crooke, S.T. The Antitumor Effects of Anthracyclines. ll. The Stereospecificity of the Carbomethoxy-group at Position 10 of the Class II Anthracycline Molecule. Mol Pharmacol 21:196-203, 1982.

Pachter, J.A., Huang, C.H., DuVernay, V.H., Prestayko, A.W. and Crooke, S.T. Viscometric and Fluorometric Studies of DNA Interactions of Several New Anthracyclines. Biochemistry 21:1541-1547, 1982.

Galvan, L. et al. Detection of a Serum DNA-Binding Protein Associated with Cancer. Cancer Res 42:1562-1566, 1982.

Galvan, L. et al. Inhibition of PM2 DNA Degradation by a Human Serum Protein. Cancer Res 42:1555-1561,1982.

Crooke, S.T. Antitumor Antibiotics 11: Actinomycin D, Bleomycin, Mitomycin C and Other Antibiotics. In Cancer Chemotherapy, Vol 3, Pinedo, H.M. (ed) Excerpta Medica, 1981, Chapter 4, 93-105.

Kalvin, D.M. et al. DNA Breakage Activity of the Methanoi Extract of Auromomycin. Cancer Chemother Pharmacol 7:41-50, 1981.

Mong, S., Daskal, Y., Prestayko, A.W. and Crooke, S.T. DNA Super coiling, Shortening and Induction of Single-Strand Regions by cis-Diamminedichloroplatinum(11). Cancer Res 41:4020-4026, 1981.

Galvan, L. et al.Inhibition of Bleomycin-induced Deoxyribonucleic Acid Breakage by Superoxide Dismutase. Cancer Res 41:5103-5106, 1981.

Huang, C.H., Mirabelli, C.K., Jan, Y. and Crooke, S.T. Single-Strand and Double-Strand DNA Breaks Produced by Several Bleomycin Analogues. Biochemistry 20:233-238, 1981.

Mirabelli, C.K. and Crooke, S.T. Comparison of the Response of Synchronized HeLa Cells to Talisomycin and Bleomycin. Cancer Chemother Pharmacol 5:251-256, 1981.

Schlein, A., Schurig, J.E., Baca, C.D., Bradner, W.T. and Crooke, S.T. Pulmonary Toxicity Studies of Bleomycin Tested Before and After Its Expiration Date. Cancer Treat Rep 65:727-728, 1981.

Schlein, A., Schurig, J.E., Baca, C., Bradner, W.T. and Crooke, S.T. Pulmonary Toxicity Studies of Bleomycin and Talisomycin. Cancer Treat Rep 65:291 -297, 1981.

Crooke, S.T. Clinical Pharmacology of Bleomycin. In Cancer and Chemotherapy, Vol. III, Antineoplastic Agents, Crooke, S.T and Prestayko, A.W. (eds), Academic Press, New York, 1981, Chapter 20, 343-350.

Crooke, S.T. The Molecular Pharmacology of Bleomycin. In Cancer and Chemotherapy, Vol. III, Antineoplastic Agents, Crooke, S.T. and Prestayko, A.W. (eds), Academic Press, New York, NY, 1981, Chapter 13, 221-232.

Crooke, S.T. The Anthracyclines. In Cancer and Chemotherapy, III, Antineoplastic Agents, Crooke, S.T. and Prestayko, A.W. (eds), Academic Press, New York, NY, 1981, Chapter 8, 111-132.

Crooke, S.T. Bleomycin, An Overview. In Cancer and Chemotherapy, Vol III, Antineoplastic Agents, Crooke, S.T. and Prestayko, A.W. (eds), Academic Press, New York, NY, 1981, Chapter 7, 97-109.

Crooke, S.T. Mitomycin C-An Overview. In Cancer and Chemotherapy, Vol. III, Antineoplastic Agents, Crooke, S.T. and Prestayko, A.W. (eds), Academic Press, New York, NY, 1981, Chapter 4, 49-60.

Crooke, S.T., DuVernay, V.H. and Mong, S. Molecular Pharmacology of Anthracyclines. In Molecular Actions and Targets for Cancer Chemotherapeutic Agents, Sartorelli, A.C., Lazo, J.S. and Bertino J.R. (eds), Academic Press, NY, 1981, Chapter 7, 137-162.

Gutierrez, M.L. et al. Phase-11 Evaluation of Mitomycin-C (MMC) in Children with Refractory Solid Tumors Using the Single High lntermittent-Dose Schedule. Med Pediatr Oncol 9:405-407, 1981.

Soloway, M.S., Murphy, W.M., Defuria, M.D., Crooke, S. and Finebaum, P. The Effect of Mitomycin-C on Superficial Bladder Cancer. J Urol 125:646-648, 1981.

Corals, R.L., Ginsberg, S.J., Reich, S.D., Baker, L.H. and Crooke, S.T. Available Data from Caminomycin Studies in the United States – The Acute Intermittent Intravenous Schedule. Recent Results Cancer Res 76:16-20, 1981.

Oken, M.M., Crooke, S.T., Elson, M., Strong, J.E. and Shafer, R.B. Pharmacokinetics of Bleomycin after Intramuscular Administration in Man. Cancer Treat Rep 65:485-489, 1981.

Reich, S. et al. Pharmacokinetics of Carminomycin in Dogs and Humans. Cancer Chemother Pharmacol 6:189-193, 1981.

Crooke, S.T. et al.Tallysomycin, A Third Generation Bleomycin Analog. In Recent Results in Cancer Research, Vol.76, Carter, S.K., Sakurai, Y. and Umezawa, H. (eds), Springer-Verlag, New York, NY, 1981, 83-90.

Crooke, S.T. et al.Cardiopulmonary Toxicities of Antineoplastic Agents. In Current Chemotherapy and Infectious Disease, Nelson, J.D. and Grassi, C. (eds), Am Society for Microbiology, 1980, 1469-1474.

Huang, C.H., Mong, S. and Crooke, S.T. Interactions of a New Antitumor Antibiotic BBM-928Awith DNA. Bifunctional Intercalative Binding Studied by Fluorometry and Viscometry. Biochemistry 19:5537-5542, 1980.

Abele, R., et al. Carminomycin (NSC-180024): A Phase I Study. Eur J Cancer 16:1555-1559, 1980.

Mirabelli, C.K., Huang, C.H. and Crooke, S.T. Comparison of DNA Damage and Single- and Double-Strand Breakage Activities on PM2 DNA by Talisomycin and Bleomycin Analogs. Cancer Res 40:4173-4177, 1980.

Seeber, S., Loth, H. and Crooke, S.T. Comparative Nuclear and Cellular Incorporation of Daunorubicin, Doxorubicin, Carminomycin, Marcellomycin, Aclacinomycin A and AD 32 in Daunorubicin-sensitive and -resistant Ehrlich Ascites in vitro. J Cancer Res Clin Oncol 98:109-118, 1980.

Bracken, R.B. et al.Role of Intravesical Mitomycin C in Management of Superficial Bladder Tumors. Urology 16:11-15, 1980.

Mong, S., Huang, C.H., Prestayko, A.W. and Crooke, S.T. Effects of Second Generation Platinum Analogs on Isolated PM2 DNA and their Cytotoxicity In vitro and In vivo. Cancer Res 40:3318-3324, 1980.

Mong, S., Huang, C.H., Prestayko, A.W. and Crooke, S.T. Interaction of Cis-Diamminedichloroplatinum II with PM2 DNA. Cancer Res 40:3313-3317, 1980.

Daskal, Y., Prestayko, A.W. and Crooke, S.T. Morphological Manifestations of Cisplatin Analogsin Rats An Ultrastructural Study. In Cisplatin Current Status and New Developments, Prestayko, A.W., Crooke, S.T. and Carter, S.K. (eds), Academic Press, New York, NY, 1980, Chapter 16, 249-269.

Mong, S., Prestayko, A.W. and Crooke, S.T. In vitro Interaction of Covalently Linked Closed Circular DNA with the Second-Generation Platinum Compounds. In Cisplatin – Current Status and New Developments, Prestayko, A.W., Crooke, S.T. and Carter, S.K. (eds), Academic Press, New York, NY, 1980, Chapter 13, 213-226.

DuVernay, V.H., Pachter, J.A. and Crooke, S.T. Molecular Pharmacological Differences Between Carminomycin and Its Analog, Carminomycin-11-methyl Ether, and Adriamycin. Cancer Res 40:387-394, 1980.

Dabrowiak, J.C., Greenaway, F.T., Santillo, F.S., Crooke, S.T. and Essery, JM. The Iron Bleomycins. In Advances in Chemistry, Martell, A.E. (ed), American Chemical Society, New York, NY, 1980.

Reich, S.D. et al.Marcellomycin. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, New York, NY, 1980, Chapter 20, 343-364.

Reich, S.D. and Crooke, S.T. Carminomycin. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, NY, 1980, Chapter 17, 295-313.

Daskal, Y. and Crooke, S.T. Ultrastructural Studies on the Effects of the Acute Administration of Anthracyclines on Nucleoli, Nucleolar Chromatin, and Metaphase Chromosomes of Various Cells and Tissues. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, New York, NY, 1980, Chapter 12, 193-219.

Crooke, S.T. and DuVernay, V.H. Fluorescence Quenching of Anthracyclines by Subcellular Fractions. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, New York, NY, 1980, Chapter 9, 151-155.

DuVernay, V.H., Mong, S. and Crooke, S.T. Molecular Pharmacology of Anthracyclines: Demonstration of Multiple Mechanistic Classes of Anthracyclines. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, NY, 1980, Chapter 6, 61-123.

Crooke, S.T. Goals for Anthracycline Analog Development at Bristol Laboratories. In Anthracyclines: Current Status and New Developments, Crooke, S.T. and Reich, S.D. (eds), Academic Press, New York, NY, 1980, Chapter 2, 11-13.

Daskal, Y., Soloway, M.S., DeFuria, M.D. and Crooke, S.T. Morphological Effects of Mitomycin C Administered Intravesically to Normal Mice and Mice with N-[4-(5-Nitro- 2-furyl)-2-thiazolyl]formamide-induced Bladder Neoplasms. Cancer Res 40:261-267, 1980.

DeFuria, M.D. et al. Phase l-ll Study of Mitomycin C Topical Therapy for Low-Grade, Low-StageTransitional Cell Carcinoma of the Bladder; An Interim Report. Cancer Treat Rep 64:225-230, 1980.

Huang, C.H., Galvan, L. and Crooke, S.T. Interactions of Bleomycin Analogues with DNA and Metal ions Studied by Fluorescence Quenching. Biochemistry 19:1761-1767, 1980.

DuVernay, V.H. and Crooke, S.T. Effects of Several Anthracycline Antitumor Antibiotics on the Transcriptional Activity of Isolated Nucleoli Antibiot (Tokyo) J Antibiot 33:1048-1053, 1980.

Crooke, S.T. Antitumor Antibiotics 11: Actinomycin D, Bleomycin, Mitomycin C and Other Antibiotics. In Cancer Chemotherapy, Vol 2, Pinedo, HM (ed), Excerpta Medica, 1980, Chapter4, 84-94.

Mong, S., DuVernay, V.H., Strong, J.E. and Crooke, S.T. Interaction of Anthracyclines with Covalently Closed Circular DNA. Mol Pharmacol 17:100-104, 1980.

Greenaway, F.T., Dabrowiak, J.C., Grulich, R. and Crooke, S.T. The 13C NMR Spectra of Tallysomycin and its Zinc(11) Complex. Organic Magnetic Resonance 13:270-273, 1980.

Gutierrez, M.L. and Crooke, S.T. Mitotane (o,p’-DDD), Cancer Treat Rev 7:49-55, 1980.

Mirabelli, C.K., Mong, S., Huang, C.H. and Crooke, S.T. Comparison of Bleomycin A2 and Talisomycin A Specific Fragmentation of Linear Duplex DNA. Biochem & Biophys Res Commun 91:871-879, 1979.

Crooke, S.T. Biochemical Effects of Drugs on the Cell Nucleus. In Effects of Drugs on the Cell Nucleus, Busch, H., Crooke, S.T. and Daskal, Y. (eds) Academic Press, New York, NY, 1979.

Reich, S.D. and Crooke, S.T. Raynaud Phenomenon. Cancer Treat Rep 63:225-226, 1979.

Prestayko, A.W., Cadiz, M. and Crooke, S.T. Incompatibility of Aluminum Containing Intravenous Administration Equipment with cis-Dichlorodiammineplatinum (II) ministration. Cancer Treat Rep 63:2118-2119, 1979.

Dabrowiak, J.C., Greenaway, F.T., Santillo, F.S. and Crooke, S.T. The Iron Complexes of Bleomycin and Tallysomycin. Biochem and Biophys Res Commun 91:721-729, 1979.

Strong, J.E. et al. Pharmacokinetics of Tallysomycin and Bleomycin in the Beagle Dog. Cancer Treat Rep 63:1821-1827, 1979.

Comis, R.L., Ginsberg, S.J., Reich, S.D., Baker, L.H. and Crooke, S.T. Available Data from Carminomycin Studies in the United States: The Acute Intermittent Intravenous Schedule. In Recent Results in Cancer Research, Carter, S.K. and Sakurai, S. (eds), Springer-Verlag, NY, 1979.

DuVernay, V.H., Pachter, J.A. and Crooke, S.T. Deoxyribonucleic Acid Binding Studies on Several New Anthracycline Antitumor Antibiotics. Sequence Preference and Structure-Activity Relationships of Marcellomycin and Its Analogues as Compared to Adriamycin. Biochemistry 18:4024-4030, 1979.

Mong, S., Strong, J.E., Bush, J.A. and Crooke, S.T. Use of Covalently Closed Circular DNA for Prescreening for Antitumor Compounds. Antimicrob Agents Chemother 16:398-405, 1979.

Mong, S., Strong, J.E. and Crooke, S.T. Interaction of Covalently Closed Circular PM2 DNA and Hedamycin. Biochem and Biophys Res Commun 88:237-243, 1979.

Merski, J.A., Daskal, Y., Crooke, S.T. and Busch, H. Acute Ultrastructural Effects of the Antitumor Antibiotic Carminomycin on Nucleoli of Rat Tissues. Cancer Res 39:1239-1244, 1979.

Sawyer, T.H. et al. Amino Terminal Amino Acid Sequence of Macromomycin, A Protein Antitumor Antibiotic. Biochim and Biophys Res Commun 86:1133-1138, 1979.

DuVernay, V.H., Pachter, J.A. and Crooke, S.T. DNA Binding Studies on Several New Anthracycline Antitumor Antibiotics II. The Importance of the Carbomethoxy-group at Position-10 of the Class II Anthracycline Molecule. Mol Pharmacol 16:623-632, 1979.

Huang, C.H., Galvan, L. and Crooke, S.T. Quenching of Fluorescence of Bleomycins by Ferrous Ion and its Correlation with DNA-Breakage Activity. Biochemistry 18:2880-2887, 1979.

Crooke, S.T. Biochemical Effects of Drugs on the Cell Nucleus. In Effects of Drugs on the Cell Nucleus. Busch, H., Crooke, S.T. and Daskal, Y. (eds), Academic Press, NY, 1979, 127-143.

Crooke, S.T. Antitumor Antibiotics Il: Actinomycin D, Bleomycin and Mitomycin C. In Cancer Chemotherapy, Vol 1, Pinedo, HM (ed) Excerpta Medica, 1979, Chapter 4, 74-92.

Comis, R.L. et al. Role of Single-Breath Carbon Monoxide-Diffusing Capacity in Monitoring the Pulmonary Effects of Bleomycin in Germ Cell Tumor Patients. Cancer Res 39:5076-5080, 1979.

D’Aoust, J.C. et al. Cisplatin, Bleomycin, and Vinblastine Combination Therapy of Testicular Tumors – An Analysis. Med Pediatr Oncol 6:195-205, 1979.

Galvan, L., Strong, J.E. and Crooke, S.T. Use of PM-2 DNA Degradation as a Pharmacokinetic Assay for Bleomycin. Cancer Res 39:3948-3951, 1979.

Baker, L.H. et al. American Experience with Carminomycin. Cancer Treat Rep 63:899-902, 1979.

Prestayko, A.W., D’Aoust, J.C., Issell, B.F. and Crooke, S.T. Cisplatin (cis-Diamminedichloroplatinum 11). Cancer Treat Rev 6:17-39, 1979.

Comis, R.L., Ginsberg, S.J. and Crooke, S.T. The Combination of Mitomycin C and Adriamycin (MA) Toxicities and Response. In Mitomycin C – Current Status and New Developments, Carter, S.K. and Crooke, S.T. (eds), Academic Press, New York, NY, 1979, Chapter 9, 83-89.

Daskal, Y. and Crooke, S.T. Morphological Effects of Mitomycin C on Cellular Fine Structure. In Mitomycin – Current Status and New Developments, Carter, S.K. and Crooke, S.T. (eds), Academic Press, NY, 1979, Chapter 5, 41 -60.

Crooke, S.T., Mitomycin, C. An Overview. In Mitomycin C – Current Status and New Developments, Carter, S.K., and Crooke, S.T. (eds), Academic Press, New York, NY, 1979, Chapter 1, 1-4.

Issell, B.F. and Crooke, S.T. Etoposide (VP-16-213). Cancer Treat Rev 6:107-124, 1979.

Gutierrez, M.L. and Crooke, S.T. Pediatric Cancer Chemotherapy: An Updated Review. Cancer Treat Rev 6:153-164, 1979.

Prestayko, A.W. et al. Antileukemic (L1210) Activity and Toxicity of cis-Dichlorodiammineplatinum(ll) Analogs. Cancer Treat Rep 63:1503-1508, 1979.

Crooke, S.T. Development of Antineoplastic Agents by Pharmaceutical Companies. Fed Proc 38:108-112, 1979.

Crooke, S.T. Macromolecular Chemotherapy. In Proceedings Medico-Pharmaceutical Forum, Cromie (ed), Oxford Press, London, 1979.

Issell, B.F., Prestayko, A.W., Comis, R.L. and Crooke, S.T. Zinostatin (Neocarzinostatin). Cancer Treat Rev 6:239-249, 1979.

Sawyer, T.H., Prestayko, A.W. and Crooke, S.T. Purification and Mechanism of Action of Macromomycin. Cancer Res 39:1180-1184, 1979.

DuVernay, V.H., Essery, J.M., Doyle, T.W., Bradner, W.T. and Crooke, S.T. The Antitumor Effects of Anthracyclines. The Importance of the Carbomethoxy-Group at Position 10 of Marcellomycin and Rudolfomycin. Pharmacol 15:341-356, 1979.

Broughton, A., Strong, J.E., Crooke, S.T., Prestayko, A.W. and Knight, J. A Radioimmunoassay for Tallysomycin. Cancer Treat Rep 63:1829-1832, 1979.

Samson, M.K. et al. Mitomycin Cin Advanced Adenocarcinoma and Large Cell Carcinoma of the Lung. Cancer Treat Rep 62:163-165, 1978.

Issell, B.F. and Crooke, S.T. Maytansine. Cancer Treat Rev 5:199-207, 1978.

Strong, J.E. and Crooke, S.T. The Use of Covalently Closed Circular DNA to Investigate Properties of Bleomycin and its Analogs. In Proceedings of Bleomycin Symposium, Umezawa, H. and Hecht, S. (eds) Springer-Verlag, New York, NY, 1978, 244-254.

Crooke, S.T. and Prestayko, A.W. The Clinical Pharmacology of Cis-Diamminedichloroplatinum, A Review. In Clinical Pharmacology of Antineoplastic Drugs, Pinedo, H.M. and Boelsma, E. (eds), Elsevier/North Holland Biomedical Press BV, Netherlands, 1978, 295-303.

Crooke, S.T., Prestayko, A.W. and Strong, J.E. Recent Advances in the Study of Clinical Pharmacology of Bleomycin. In Clinical Pharmacology of Antineoplastic Drugs, Pinedo, H.M., Boelsma, E. (eds), Elsevier/North Holland Biomedical Press BV, Netherlands, 1978, 225-244.

Crooke, S.T., Einhorn, L.H., Comis, R.L., D’Aoust, J.C. and Prestayko, A.W. The Effects of Prior Exposure to Bleomycin on the Incidence of Pulmonary Toxicities in a Group of Patients with Disseminated Testicular Carcinomas. Med and Pediatr Oncol 5:93-98, 1978.

Prestayko, A.W., Luft, F., Einhorn, L.H. and Crooke, S.T. Cisplatin Pharmacokinetics in a Patient with Renal Dysfunction. Med Pediatr Oncol 5:183-188, 1978.

Strong, J.E. and Crooke, S.T. DNA Breakage by Tallysomycin. Cancer Res 38:3322-3326, 1978.

Greenaway, F.T., Dabrowiak, J.C., Van Husen, M., Grulich, R. and Crooke, S.T. The Transition Metal Binding Properties of a 3rd Generation Bleomycin Analogue, Tallysomycin. Biophys Res Commun 85:1407-1414, 1978.

Broughton, A., Strong J.E., Crooke, S.T. and Prestayko, A.W. The Development and Use of Radioimmunoassays in the Study of the Pharmacology of Anticancer Drugs. In Advances in Cancer Chemotherapy, Carter, C.K., Goldin, A., Kuretani, K., Mathe, G., Sakurai, Y., Tsukagoshi, S. and Umezawa, H. (eds), University of Tokyo Press, Tokyo, Japan, 1978, 267-282.

Elson, M.K. et al. Comparison of Two Radioimmunoassays and a Microbiologic Assay for Bleomycin. Med Pediatr Oncol 5:213-218, 1978.

Crooke, S.T. Bleomycin – Future Directions (Preclinical). In Bleomycin: Current Status and New Developments, Carter, S.K., Crooke, S.T. and Umezawa, H. (eds), Academic Press, NY, 1978, Chapter 30, 357-365.

Strong, J.E. and Crooke, S.T. Mechanism of Action of Tallysomycin, A Third Generation Bleomycin. In Bleomycin: Current Status and New Developments, Carter, S.K., Crooke, S.T. and Umezawa, H. (eds), Academic Press, New York, NY, 1978, Chapter 29, 343-355.

Prestayko, A.W. and Crooke, S.T. Clinical Pharmacology of Bleomycin. In Bleomycin: Current Status and New Developments, Carter, S.K., Crooke, S.T. and Umezawa, H. (eds), Academic Press, New York, NY, 1978, Chapter 10, 117-130.

Crooke, S.T. Bleomycin, A Brief Review. In Bleomycin: Current Status and New Developments, Carter, S.K., Crooke, S.T. and Umezawa, H. (eds), Academic Press, New York, NY, 1978, Ch 10, 118-130.

Daskal, Y., Woodard, C., Crooke, S.T. and Busch, H. Comparative Ultrastructural Studies of Nucleoli of Tumor Cells Treated with Adriamycin and the Newer Anthracyclines, Carminomycin and Marcellomycin. Cancer Res 38:467-473, 1978.

Crooke, S.T., DuVernay, V., Galvan, L. and Prestayko, A.W. Structure-Activity Relationships of Anthracyclines Relative to Effects on Macromolecular Syntheses. Mol Pharmacol 14:290-298, 1978.

Dabrowiak, J.C., Greenaway, F.I., Longo, W.E., VanHusen, M. and Crooke, S.T. A Spectroscopic Investigation of the Metal Binding Site of Bleomycin A2. The Cu(11) and Zn(11) Derivatives. Biochim Biophys Acta 517:517-526, 1978.

Prestayko, A.W., DuVernay, V., Galvan, L. and Crooke, S.T. Structure-Activity Relationships of Anthracyclines Relative to Effects on Macromolecules. In: Current Chemotherapy – Proceedings of the 10th International Congress of Chemotherapy, Vol. ll, Siegenthaler, W. and Luthy, R. (eds), American Society for Microbiology, Washington, DC, 1978, 1239-1240.

Corals, R.L. et al. The Effects of Bleomycin on Carbon Monoxide Diffusion Capacity in Patients with Testicular Carcinomas. In: Current Chemotherapy – Proceedings of the 10th International Congress of Chemotherapy, Vol. ll, Siegenthaler, W. and Luthy, R. (eds), American Society for Microbiology, Washington, DC, 1135-1137, 1978.

Crooke, S.T. et al. Studies on the Clinical Pharmacology of Bleomycin. In Recent Results in Cancer Research, Vol. 63, Carter, S.K., Umezawa, H. and Samurai, Y. (eds), Springer-Verlag, New York, NY, 1978, Chapter 20, 219-229.

Crooke, S.T. et al. Effects of Variations in Renal Function on the Clinical Pharmacology of Bleomycin Administered as an Intravenous Bolus. Cancer Treatment Rep 61:1631-1636, 1977.

Crooke, S.T. Antitumor Antibiotics, A Review. Hall, T.C. (ed), Medical Oncology Review, American College of Physicians, 1977.

Crooke, S.T and Prestayko, A.W. Bleomycin Pharmacokinetics in Patients with Normal and Impaired Renal Function. Proceedings International Congress of Chemotherapy 99-103, 1977.

Strong, J., Broughton, A. and Crooke, S.T. Specificity of Antiserum Produced Against Bleomycin. Cancer Treat Rep 61:1509-1512, 1977.

Crooke, S.T. A Review of Carminomycin – A New Anthracycline Developed in the USSR. J Med 8:295-316, 1977.

Crooke, S.T. et al. Bleomycin Serum Pharmacokinetics as Determined by a Radioimmunoassay and a Microbiologic Assay in a Patient with Compromised Renal Function. Cancer 39:1430-1434, 1977.

Crooke, S.T., Henderson, M., Samson, M. and Baker, L.H. Phase I Study of Oral Mitomycin C. Cancer Treatment Rep 60:1633- 1636, 1976.

Johnson, D.E., Bracken, B., Prestayko, A.W., Brown, T.E. and Crooke, S.T. Intravesical Administration of Bleomycin in the Treatment of Bladder Cancer. JAMA 236:1353-1354, 1976.

Crooke, S.T. and Bradner, W.T. Bleomycin, A Review. J Med 7:333-428, 1976.

Crooke, S.T. and Bradner, W.T. Mitomycin C: A Review. Cancer Treat Rev 3:121 -139, 1976.

Crooke, S.T., Sitz, T.O., Bannon, M. and Busch, H. Biochemical Effects of Bleomycin A2 on Novikoff Hepatoma Ascites Cells. Physiol Chem Phys 7:177-190, 1975.

Daskal, Y., Crooke, S.T., Smetana, K. and Busch, H. Ultrastructural Study of the Effects of Bleomycin A2 on the Nucleolus and its Possible Related Cytoplasmic Constituents in Novikoff Hepatoma Cells. Cancer Res 35:374-381, 1975.

Crooke, S.T. Solvent Inhalation. Texas Medicine 68:67-70, 1972.

Crooke, S.T., Okada, S. and Busch, H. A Surface 3/-Exonuclease of Novikoff Hepatoma Ascites Cells. Cancer Res 32:1745-1752, 1972.

McParland, R., Crooke, S.T. and Busch, H. Rat Liver Nuclear Ribonucleoprotein Particles: Reassociation of Residues with Various Types of RNA. Biochim Biophys Acta 269:78-89, 1972.

Busch, H., Choi, Y.C., Crooke, S.T. and Okada, S. Genetic Engineering and Cancer Chemotherapy. Oncology 26:152-179, 1972.

Busch, H. et al. Low Molecular Weight Nuclear RNAs. Perspect Biol Med 15:117-139, 1971.

Crooke, S., Okada, S. and Busch, H. Uptake of Exogenous tRNA by Novikoff Hepatoma Ascites Cells. Soc Exp Biol Med 137:837-846, 1971.

 

 

BOOKS

Boulikas, T. (ed), Crooke, S.T. (assoc ed) Gene Therapy & Molecular Biology from Basic Mechanisms to Clinical Applications, Vol 11, No 2, Gene Therapy Press, 2008.

Crooke, S.T. (ed) Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition, CRC Press, 2007.

Crooke, S.T. (ed) Antisense Drug Technology: Principles, Strategies, and Applications, Marcel Dekker, Inc, 2001.

Crooke, S.T. (ed) Antisense Research and Application. Handbook of Experimental Pharmacology, Springer-Verlag, Berlin Heidelberg, 1998.

Crooke, S.T. Therapeutic Applications of Oligonucleotides, RG Landes Co, Austin, TX, 1995.

Crooke, S.T. and Lebleu, B. (eds) Antisense Research and Applications, CRC Press, Inc, Boca Raton, FL, 1993.

Crooke, S.T. and Wong, A. (eds) Lipoxvaenases and Their Products, Academic Press, Inc, 1991.

Poste, G and Crooke, ST (eds) New Horizons in Therapeutics V. Cellular and Molecular Aspects of Inflammation, Plenum Press, NY, 1988.

Poste, G. and Crooke, S.T. (eds) New Horizons in Therapeutics IV. New Frontiers in the Study of Gene Functions, Plenum Press, NY, 1987.

Poste, G. and Crooke, S.T. (eds) New Horizons in Therapeutics III. New Insights into Cell and Membrane Transport Processes, Plenum Press, NY, 1986.

Poste, G. and Crooke, S.T. (eds) New Horizons in Therapeutics II. Mechanisms of Receptor Regulation, Plenum Press, NY, 1985.

Poste, G. and Crooke, S.T. (eds) New Horizons in Therapeutics I. Dopamine Receptor Agonists, Plenum Press, NY, 1984.

Prestayko, A.W., Crooke, S.T., Baker, L.H., Carter, S.T. and Schein, P.S. (eds) Nitrosoureas: Current Status and New Developments, Academic Press, NY, 1981.

Crooke, S.T. and Prestayko, A.W. (eds) Cancer and Chemotherapy – III. Antineoplastic Agents, Academic Press, NY, 1981.

Crooke, S.T. and Prestayko, A.W. (eds) Cancer and Chemotherapy – II. Introduction to Clinical Oncology, Academic Press, NY, 1981.

Crooke, S.T. and Prestayko, A.W. (eds) Cancer and Chemotherapy – I. Introduction to Neoplasia and Antineoplastic Chemotherapy, Academic Press, NY, 1980.

Prestayko, A.W., Crooke, S.T. and Carter, S.K. (eds) Cisplatin – Current Status and New Developments, Academic Press, NY, 1980.

Crooke, S.T. and Reich, S.D. (eds) Anthracyclines: Current Status and New Developments, Academic Press, NY, 1980.

Busch, H., Crooke, S.T. and Daskal, Y. (eds) Effects of Drugs on the Cell Nucleus, Academic Press, NY, 1979.

Carter, S.K. and Crooke, S.T. (eds), Mitomycin C: Current Status and New Developments, Academic Press, NY, 1979.

Carter, S.K., Crooke, S.T. and Umezawa, H. (eds) Bleomycin: Current Status and New Developments, Academic Press, NY, 1978.

Leave a Comment